

Pfizer Inc. Revenues
Nine Months 2020 and 2019
Unaudited
(millions of dollars)
Quarter-to-Date

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL ^(a)				DEVELOPED EUROPE ^(b)				DEVELOPED REST OF WORLD ^(b)				EMERGING MARKETS ^(b)			
			% of Change				% of Change			% of Change				% of Change				% of Change				% of Change	
	2020	2019	Reported	Operational	2020	2019	Reported	2020	2019	Reported	Operational	2020	2019	Reported	Operational	2020	2019	Reported	Operational	2020	2019	Reported	Operational
TOTAL REVENUES	35,961	39,062	(8%)	(7%)	16,770	18,360	(9%)	19,191	20,701	(7%)	(5%)	6,095	6,450	(5%)	(4%)	4,642	4,758	(2%)	(2%)	8,453	9,493	(11%)	(6%)
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)	30,017	28,429	6%	7%	15,621	14,270	9%	14,396	14,160	2%	5%	5,437	5,456	—	1%	2,974	2,762	8%	8%	5,986	5,941	1%	7%
Internal Medicine^(b)	6,695	6,508	3%	4%	3,635	3,569	2%	3,059	2,939	4%	7%	1,414	1,288	10%	11%	690	680	1%	2%	955	971	(2%)	6%
Eliquis alliance revenues and direct sales	3,686	3,121	18%	19%	2,084	1,768	18%	1,602	1,353	18%	21%	899	786	14%	16%	297	260	14%	14%	407	307	32%	40%
Chantix/Champix	728	825	(12%)	(11%)	575	666	(14%)	153	159	(4%)	(1%)	79	60	33%	35%	47	53	(12%)	(11%)	27	46	(41%)	(38%)
Premarin family	471	542	(13%)	(13%)	441	510	(14%)	31	32	(4%)	—	1	1	(14%)	(13%)	16	15	3%	5%	14	16	(11%)	(4%)
BMP2	197	212	(7%)	(7%)	197	212	(7%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Toviaz	183	186	(2%)	(1%)	57	55	5%	126	132	(5%)	(4%)	47	50	(4%)	(3%)	70	74	(5%)	(5%)	8	8	(5%)	1%
All other Internal Medicine	1,429	1,621	(12%)	(9%)	282	359	(21%)	1,147	1,262	(9%)	(5%)	387	391	(1%)	—	261	277	(6%)	(6%)	499	593	(16%)	(8%)
Oncology	7,843	6,547	20%	21%	5,103	4,031	27%	2,741	2,516	9%	12%	1,219	1,248	(2%)	(1%)	574	487	18%	18%	947	782	21%	30%
Ibrance	3,955	3,677	8%	9%	2,689	2,405	12%	1,266	1,273	(1%)	3%	640	742	(14%)	(13%)	288	241	19%	19%	339	290	17%	30%
Xtandi alliance revenues	741	594	25%	25%	741	594	25%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Sutent	616	704	(13%)	(10%)	169	217	(22%)	448	488	(8%)	(5%)	184	218	(15%)	(14%)	68	77	(11%)	(11%)	195	193	1%	9%
Inlyta	559	316	77%	79%	372	185	*	187	131	43%	47%	61	29	*	*	59	51	15%	14%	67	50	33%	43%
Xalkori	409	385	6%	8%	106	111	(5%)	303	274	11%	14%	76	85	(10%)	(9%)	35	37	(5%)	(4%)	192	152	26%	31%
Bosulif	324	267	21%	21%	220	178	23%	105	89	17%	18%	52	46	15%	16%	40	34	17%	16%	12	10	27%	31%
Retacrit ^(c)	278	147	90%	90%	204	86	*	74	60	22%	24%	70	59	18%	20%	—	—	—	—	4	1	*	*
Lorbrena	142	77	85%	85%	81	54	52%	61	23	*	*	26	5	*	*	27	18	55%	53%	8	—	*	*
Braftovi	116	18	*	*	115	18	*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Mektovi	103	19	*	*	103	19	*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Ruxience ^(c)	78	—	*	*	76	—	*	1	—	*	*	—	—	—	—	1	—	*	*	—	—	—	—
All other Oncology	522	342	52%	54%	228	164	39%	295	178	65%	69%	110	64	71%	71%	55	29	92%	92%	129	85	52%	59%
Hospital^{(a)(d)}	5,535	5,505	1%	2%	2,279	2,052	11%	3,256	3,453	(6%)	(3%)	664	662	—	2%	526	563	(7%)	(5%)	2,066	2,228	(7%)	(4%)
Sulperazon	432	505	(14%)	(12%)	—	—	—	432	505	(14%)	(12%)	—	—	—	—	6	6	(7%)	(9%)	426	498	(15%)	(13%)
Medrol	295	348	(15%)	(15%)	147	187	(21%)	147	161	(9%)	(7%)	39	50	(21%)	(21%)	30	30	(2%)	(2%)	78	81	(4%)	(1%)
Zithromax	218	254	(14%)	(13%)	4	(1)	*	214	255	(16%)	(14%)	34	37	(8%)	(6%)	21	28	(25%)	(25%)	160	190	(16%)	(14%)
Precedex	211	116	82%	87%	148	46	*	63	70	(10%)	(3%)	—	—	—	—	22	41	(45%)	(45%)	41	30	37%	54%
Vfend	201	265	(24%)	(22%)	17	11	60%	183	255	(28%)	(26%)	12	16	(23%)	(21%)	41	54	(23%)	(23%)	130	185	(30%)	(27%)
Panzyga	199	107	85%	85%	199	107	85%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Fragmin	178	185	(4%)	(2%)	5	7	(23%)	172	178	(3%)	(1%)	85	85	—	1%	42	46	(8%)	(6%)	45	47	(5%)	—
Zyvox	176	195	(10%)	(7%)	17	23	(27%)	159	172	(10%)	(5%)	7	10	(25%)	(24%)	20	37	(46%)	(46%)	132	125	5%	9%
Pfizer CentreOne ^(e)	618	566	11%	12%	286	296	(3%)	332	260	28%	29%	147	116	26%	27%	25	12	*	*	160	132	21%	23%
All other Anti-infectives	1,195	1,260	(5%)	(2%)	321	378	(15%)	874	881	(1%)	3%	223	225	(1%)	—	75	84	(11%)	(11%)	577	572	1%	7%
All other Hospital ^(d)	1,813	1,713	6%	7%	1,134	997	14%	679	716	(5%)	(3%)	116	123	(5%)	(4%)	244	227	8%	11%	318	367	(13%)	(11%)
Vaccines	4,574	4,795	(5%)	(3%)	2,217	2,607	(15%)	2,357	2,189	8%	11%	771	723	7%	8%	322	287	12%	13%	1,264	1,178	7%	13%
Prevnar 13/Prevnar 13	4,100	4,268	(4%)	(2%)	2,143	2,498	(14%)	1,957	1,770	11%	14%	481	409	18%	19%	308	265	16%	17%	1,168	1,096	7%	12%
Nimenrix	180	159	13%	17%	—	—	—	180	159	13%	17%	103	91	14%	16%	12	18	(33%)	(30%)	65	51	28%	36%
FSME/MMUN-TicoVac	170	197	(14%)	(13%)	—	—	—	170	197	(14%)	(13%)	142	170	(16%)	(16%)	—	—	0%	0%	27	27	2%	5%
All other Vaccines	124	171	(27%)	(27%)	74	108	(32%)	50	63	(20%)	(18%)	44	54	(17%)	(15%)	2	4	(38%)	(37%)	4	5	(31%)	(27%)
Inflammation & Immunology (I&I)	3,299	3,482	(5%)	(4%)	1,534	1,504	2%	1,766	1,978	(11%)	(8%)	809	994	(19%)	(18%)	462	464	—	—	495	520	(5%)	4%
Xeljanz	1,741	1,634	6%	8%	1,213	1,201	1%	528	434	22%	26%	199	172	16%	17%	188	148	27%	28%	141	114	24%	38%
Enbrel (Outside the U.S. and Canada)	1,005	1,285	(22%)	(19%)	—	—	—	1,005	1,285	(22%)	(19%)	462	633	(27%)	(26%)	205	262	(22%)	(22%)	337	391	(14%)	(6%)
Inflectra/RemSima ^(f)	471	446	6%	7%	244	208	17%	227	238	(5%)	(2%)	172	201	(14%)	(13%)	38	21	79%	84%	16	15	6%	23%
All other I&I	83	116	(28%)	(29%)	77	95	(19%)	6	22	(70%)	(73%)	(24)	(11)	*	*	30	33	(8%)	(10%)	—	—	—	—
Rare Disease	2,071	1,592	30%	32%	854	508	68%	1,218	1,084	12%	15%	559	541	3%	5%	399	281	42%	41%	259	262	(1%)	8%
Vyndaqel/Vyndamax	859	259	*	*	431	87	*	429	173	*	*	183	99	84%	85%	218	57	*	*	28	16	77%	87%
BeneFIX	337	372	(9%)	(8%)	176	190	(7%)	161	181	(11%)	(8%)	57	76	(25%)	(24%)	48	55	(13%)	(10%)	57	51	11%	19%
Genotropin	316	357	(12%)	(10%)	92	57	62%	224	300	(25%)	(23%)	96	118	(19%)	(17%)	79	112	(29%)	(30%)	48	69	(31%)	(22%)
Refacto AF/Xyntha	272	319	(14%)	(12%)	54	71	(23%)	218	248	(12%)	(9%)	118	144	(17%)	(16%)	24	30	(20%)	(17%)	74	74	2%	7%
Somavert	198	192	3%	4%	76	75	1%	123	117	4%	6%	96	93	2%	4%	16	14	16%	16%	11	11	6%	17%
All other Rare Disease	89	94	(5%)	2%	25	29	(13%)	64	65	(2%)	9%	10	11	(10%)	(8%)	14	14	7%	10%	40	41	(3%)	13%
UPJOHN^(g)	5,944	8,535	(30%)	(29%)	1,149	3,103	(63%)	4,795	5,432	(12%)	(10%)	659	693	(5%)	(4%)	1,							

Pfizer Inc. Revenues
Third Quarter 2020 and 2019
Unaudited
(millions of dollars)
Quarter-to-Date

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL ^(a)				DEVELOPED EUROPE ^(b)				DEVELOPED REST OF WORLD ^(b)				EMERGING MARKETS ^(b)				
			% of Change				% of Change			% of Change				% of Change				% of Change						
	2020	2019	Reported	Operational	2020	2019	Reported	2020	2019	Reported	Operational	2020	2019	Reported	Operational	2020	2019	Reported	Operational	2020	2019	Reported	Operational	
TOTAL REVENUES	12,131	12,680	(4%)	(4%)	5,716	5,850	(2%)	6,415	6,830	(6%)	(5%)	2,087	2,135	(2%)	(4%)	1,634	1,585	3%	3%	2,694	3,110	(13%)	(9%)	
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)	10,215	9,952	3%	4%	5,363	5,142	4%	4,852	4,811	1%	3%	1,864	1,835	2%	—	1,066	955	12%	11%	1,923	2,020	(5%)	1%	
Internal Medicine^(b)	2,085	2,128	(2%)	(1%)	1,063	1,126	(6%)	1,022	1,002	2%	4%	467	442	6%	4%	251	229	9%	9%	304	330	(8%)	1%	
Eliquis alliance revenues and direct sales	1,114	1,025	9%	9%	557	541	3%	557	484	15%	16%	308	282	9%	7%	112	90	25%	25%	138	113	22%	31%	
Chantix/Champix	223	276	(19%)	(19%)	185	227	(19%)	38	49	(23%)	(22%)	16	18	(10%)	(12%)	15	18	(18%)	(18%)	8	14	(46%)	(42%)	
Premarin family	168	182	(8%)	(7%)	157	170	(8%)	11	11	(7%)	(2%)	-	-	0%	0%	6	5	17%	18%	4	6	(27%)	(19%)	
BMP2	70	66	5%	5%	70	66	5%	-	-	-	-	-	-	0%	0%	-	-	-	-	-	-	-	-	
Toviaz	59	61	(4%)	(4%)	16	18	(11%)	43	43	(1%)	(1%)	16	16	(3%)	(4%)	24	24	3%	3%	2	3	(21%)	(15%)	
All other Internal Medicine	451	517	(13%)	(10%)	78	103	(25%)	373	414	(10%)	(6%)	127	126	1%	(1%)	94	93	1%	1%	153	195	(22%)	(13%)	
Oncology	2,761	2,350	18%	18%	1,793	1,466	22%	968	884	10%	11%	441	434	1%	(1%)	215	172	25%	25%	313	277	13%	22%	
Ibrance	1,357	1,283	6%	6%	909	832	9%	448	451	(1%)	(1%)	223	265	(16%)	(17%)	108	88	23%	23%	117	99	17%	31%	
Xtandi alliance revenues	266	225	18%	18%	266	225	18%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Sutent	202	224	(10%)	(8%)	56	64	(13%)	146	160	(9%)	(6%)	60	67	(11%)	(12%)	24	26	(9%)	(9%)	62	67	(6%)	2%	
Inlyta	195	139	41%	41%	124	92	34%	71	46	53%	55%	26	10	*	*	22	17	34%	34%	22	20	11%	20%	
Xalkori	122	130	(6%)	(5%)	29	36	(20%)	93	94	(1%)	(1%)	25	27	(8%)	(10%)	12	12	4%	4%	56	55	2%	6%	
Bosulif	111	90	23%	23%	74	61	22%	37	30	25%	24%	19	15	28%	25%	15	12	24%	23%	3	3	12%	17%	
Retacrit ^(c)	102	64	59%	58%	75	42	78%	27	22	21%	19%	24	22	13%	11%	-	-	-	-	2	1	*	*	
Lobrena	55	32	69%	68%	32	21	52%	23	12	*	98%	10	5	*	*	10	7	45%	45%	3	-	*	*	
Braftovi	42	18	*	*	42	18	*	-	-	0%	0%	-	-	-	-	-	-	-	-	-	-	-	0%	0%
Mektovi	34	19	81%	81%	34	19	79%	-	-	0%	0%	-	-	-	-	-	-	-	-	-	-	0%	0%	
Ruxience ^(c)	59	*	*	*	58	*	*	1	*	*	*	-	-	-	-	1	-	*	*	-	-	-	-	
All other Oncology	217	125	74%	75%	95	56	70%	122	69	77%	79%	52	25	*	*	23	11	*	*	47	33	41%	50%	
Hospital^{(a)(d)}	1,728	1,840	(6%)	(5%)	703	683	3%	1,025	1,157	(11%)	(9%)	209	211	(1%)	(3%)	180	197	(9%)	(9%)	637	749	(15%)	(11%)	
Sulperazon	143	163	(12%)	(11%)	-	-	-	143	163	(12%)	(11%)	-	-	-	-	2	2	(6%)	(7%)	141	161	(12%)	(11%)	
Medrol	87	109	(20%)	(19%)	40	54	(27%)	48	55	(12%)	(11%)	12	16	(24%)	(25%)	9	11	(13%)	(13%)	26	28	(6%)	(2%)	
Zithromax	25	77	(68%)	(67%)	1	2	(70%)	24	75	(68%)	(67%)	5	10	(49%)	(50%)	5	8	(42%)	(42%)	14	57	(75%)	(74%)	
Precedex	55	36	52%	59%	30	14	*	25	22	14%	26%	-	-	-	-	5	13	(58%)	(58%)	20	10	*	*	
Vfend	52	87	(41%)	(39%)	3	3	(24%)	49	84	(42%)	(40%)	3	5	(34%)	(35%)	13	17	(26%)	(26%)	33	61	(47%)	(44%)	
Panznya	62	46	35%	35%	62	46	35%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fragmin	60	62	(3%)	(3%)	2	3	(39%)	58	60	(2%)	(1%)	28	27	1%	(1%)	4	15	(10%)	(8%)	17	17	(1%)	4%	
Zyvox	51	61	(17%)	(15%)	5	5	5%	45	56	(19%)	(17%)	2	4	(32%)	(33%)	8	10	(27%)	(27%)	35	42	(16%)	(13%)	
Pfizer CentreOne ^(e)	242	176	37%	38%	111	101	11%	131	75	73%	74%	53	30	73%	71%	12	5	*	*	66	40	65%	68%	
All other Anti-infectives	384	434	(12%)	(9%)	106	131	(20%)	278	303	(8%)	(4%)	72	76	(5%)	(7%)	25	28	(13%)	(13%)	181	199	(9%)	(2%)	
All other Hospital ^(d)	568	589	(4%)	(3%)	344	324	6%	224	265	(16%)	(15%)	34	43	(23%)	(24%)	87	87	-	1%	103	134	(23%)	(22%)	
Vaccines	1,717	1,808	(5%)	(4%)	913	1,078	(15%)	804	730	10%	12%	271	234	16%	14%	122	93	31%	31%	411	403	2%	6%	
Prevnar 13/Prevnar 13	1,534	1,603	(4%)	(3%)	868	1,008	(14%)	665	595	12%	14%	163	132	24%	22%	117	87	35%	35%	386	376	2%	7%	
Nimenrix	50	52	(3%)	(3%)	-	-	-	50	52	(3%)	(3%)	33	30	8%	7%	4	5	(24%)	(24%)	14	17	(18%)	(14%)	
FSME/IMMUN-TicoVac	77	64	20%	18%	-	-	-	77	64	20%	18%	66	55	19%	18%	-	-	-	-	11	9	24%	25%	
All other Vaccines	56	89	(37%)	(37%)	44	70	(37%)	12	19	(39%)	(38%)	10	17	(41%)	(41%)	1	1	(1%)	1%	1	2	(37%)	(35%)	
Inflammation & Immunology (I&I)	1,173	1,226	(4%)	(3%)	592	566	5%	581	660	(12%)	(10%)	265	328	(19%)	(21%)	157	162	(3%)	(3%)	159	170	(6%)	3%	
Xeljanz	654	599	9%	10%	469	444	6%	185	154	20%	23%	69	62	12%	9%	71	55	29%	29%	45	38	20%	35%	
Enbrel (Outside the U.S. and Canada)	321	415	(23%)	(21%)	-	-	-	321	415	(23%)	(21%)	149	199	(25%)	(27%)	64	88	(27%)	(28%)	108	128	(15%)	(7%)	
Inflectra/Remsima ^(c)	162	155	5%	5%	88	77	15%	74	78	(5%)	(5%)	56	65	(13%)	(14%)	12	9	39%	41%	5	5	10%	32%	
All other I&I	35	58	(39%)	(38%)	34	45	(24%)	1	12	(92%)	(91%)	(10)	2	*	*	11	11	(1%)	(2%)	-	-	-	-	
Rare Disease	752	601	25%	26%	300	222	35%	452	379	19%	20%	212	186	14%	12%	142	103	38%	38%	99	91	9%	17%	
Vyndarel/Vyndamax	351	156	*	*	158	79	*	193	77	*	*	90	40	*	*	86	29	*	*	17	8	*	*	
BeneFIX	107	125	(14%)	(13%)	54	66	(17%)	53	59	(10%)	(9%)	19	25	(23%)	(25%)	14	17	(17%)	(16%)	20	17	14%	22%	
Genotropin	107	124	(14%)	(13%)	37	23	59%	70	101	(31%)	(30%)	30	39	(23%)	(25%)	24	37	(37%)	(37%)	17	25	(34%)	(26%)	
Refacto AF/Xyntha	92	104	(12%)	(11%)	18	22	(20%)	74	82	(10%)	(9%)	38	48	(21%)	(22%)	7	9	(27%)	(27%)	29	25	19%	24%	
Somavert	67	64	5%	4%	25	24	4%	42	40	5%	4%	33	31	5%	4%	6	5	12%	13%	3	4	(10%)	(2%)	
All other Rare Disease	27	28	(2%)	8%	7	8	(5%)	20	20	(1%)	12%	2	3	(22%)	(22%)	5	5	14%	15%	12	12	(2%)	19%	
UPJOHN^(b)	1,916	2,351	(18%)	(18%)	354	585	(40%)	1,563	1,766	(12%)	(10%)	222	233	(4%)	(6%)	569	578	(2%)	(2%)	772	955	(19%)	(17%)	
Lipitor	356	476	(25%)	(24%)	20	25	(21%)	336	451	(26%)	(25%)	36	43	(16%)	(17%)	45	43	3%	4%	255	365	(30%)	(29%)	
Lyrica	352	527	(33%)	(33%)	43	200	(78%)	308	326	(6%)	(5%)	37	45	(17%)	(19%)	215	201	7%	6%	56	80	(30%)	(27%)	

Pfizer Inc. Revenues
Second Quarter 2020 and 2019
Unaudited
(millions of dollars)
Quarter-to-Date

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL ^(a)				DEVELOPED EUROPE ^(b)				DEVELOPED REST OF WORLD ^(b)				EMERGING MARKETS ^(b)			
			% of Change				% of Change			% of Change				% of Change		% of Change				% of Change			
	2020	2019	Reported	Operational	2020	2019	Reported	2020	2019	Reported	Operational	2020	2019	Reported	Operational	2020	2019	Reported	Operational	2020	2019	Reported	Operational
TOTAL REVENUES	11,801	13,264	(11%)	(9%)	5,402	6,335	(15%)	6,399	6,929	(8%)	(4%)	2,088	2,228	(6%)	(3%)	1,552	1,639	(5%)	(5%)	2,759	3,062	(10%)	(3%)
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)	9,795	9,432	4%	6%	5,045	4,667	8%	4,750	4,765	—	5%	1,864	1,860	—	3%	989	929	6%	7%	1,897	1,977	(4%)	4%
Internal Medicine^(c)	2,279	2,243	2%	4%	1,225	1,262	(3%)	1,054	981	7%	13%	492	418	18%	22%	228	239	(5%)	(4%)	334	324	3%	14%
Eliquis alliance revenues and direct sales	1,272	1,085	17%	19%	722	626	15%	550	459	20%	25%	313	265	18%	23%	98	91	7%	7%	139	103	35%	47%
Chantix/Champix	235	276	(15%)	(14%)	179	227	(21%)	56	49	15%	20%	30	22	34%	39%	17	18	(6%)	(3%)	9	8	12%	19%
Premarin family	152	193	(21%)	(21%)	142	182	(22%)	10	11	(7%)	1%	—	—	—	—	5	5	(8%)	(5%)	5	5	(5%)	8%
BMP2	57	79	(27%)	(27%)	57	79	(27%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Toviaz	64	65	(1%)	—	22	19	14%	42	46	(8%)	(7%)	16	17	(4%)	(1%)	23	26	(10%)	(11%)	3	3	(6%)	2%
All other Internal Medicine	498	544	(9%)	(4%)	102	128	(20%)	396	416	(5%)	1%	133	114	17%	20%	85	97	(13%)	(12%)	178	205	(13%)	(3%)
Oncology	2,647	2,236	18%	20%	1,738	1,386	25%	909	851	7%	12%	414	420	(2%)	2%	193	162	19%	19%	302	269	13%	23%
Ibrance	1,349	1,261	7%	9%	927	831	11%	422	430	(2%)	3%	219	250	(12%)	(10%)	95	79	20%	20%	108	101	8%	21%
Xtandi alliance revenues	266	201	32%	32%	266	201	32%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Sutent	209	248	(16%)	(13%)	61	82	(26%)	148	166	(11%)	(6%)	62	74	(16%)	(13%)	23	25	(6%)	(5%)	62	67	(8%)	1%
Inlyta	195	104	87%	89%	132	60	*	63	44	43%	48%	20	10	90%	96%	12	18	18%	16%	22	16	39%	52%
Xalkori	138	133	4%	7%	37	41	(8%)	100	92	9%	14%	28	29	(1%)	2%	21	13	(2%)	(1%)	60	51	18%	25%
Bosulif	113	97	17%	18%	78	64	22%	36	33	7%	9%	18	16	15%	18%	14	12	15%	12%	4	5	(31%)	(25%)
Retacrit ^(c)	87	51	69%	70%	63	30	*	24	21	12%	15%	23	21	9%	12%	—	—	—	—	1	—	*	*
Braftovi	36	—	*	*	36	—	*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Mektovi	32	—	*	*	32	—	*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
All other Oncology	221	140	57%	60%	105	76	37%	116	64	81%	88%	43	20	*	*	27	15	77%	76%	46	29	60%	70%
Hospital^{(a)(d)}	1,794	1,838	(2%)	—	762	676	13%	1,032	1,161	(11%)	(7%)	248	231	7%	10%	178	182	(2%)	1%	607	748	(19%)	(14%)
Sulperazon	102	165	(38%)	(36%)	—	—	—	102	165	(38%)	(36%)	—	—	—	—	2	2	(14%)	(17%)	100	163	(39%)	(36%)
Medrol	78	120	(35%)	(33%)	30	63	(51%)	48	57	(16%)	(13%)	12	17	(30%)	(27%)	10	12	(15%)	(15%)	26	28	(9%)	(4%)
Zithromax	55	73	(24%)	(22%)	—	—	—	55	73	(25%)	(22%)	14	12	16%	19%	7	9	(19%)	(19%)	33	52	(35%)	(33%)
Precedex	114	40	*	*	94	14	*	21	25	(17%)	(8%)	—	—	—	—	8	14	(42%)	(41%)	13	11	15%	35%
Vfend	75	94	(20%)	(17%)	14	3	*	61	90	(32%)	(29%)	5	5	(13%)	(10%)	14	19	(27%)	(28%)	43	66	(35%)	(30%)
Panzylga	63	44	42%	42%	63	44	42%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Zyvox	55	71	(22%)	(19%)	5	13	(58%)	50	58	(15%)	(10%)	3	3	(14%)	(11%)	6	13	(54%)	(54%)	41	41	(2%)	4%
Fragmin	58	63	(8%)	(3%)	2	2	(30%)	57	61	(7%)	(2%)	29	29	—	4%	15	17	(7%)	(3%)	12	15	(19%)	(12%)
Pfizer CentreOne ^(e)	224	204	10%	11%	99	98	1%	125	106	18%	21%	58	48	19%	21%	7	4	87%	85%	60	54	12%	16%
All other Anti-infectives	367	420	(13%)	(8%)	78	119	(34%)	289	301	(4%)	2%	80	78	2%	5%	26	29	(11%)	(9%)	183	194	(6%)	3%
All other Hospital ^(d)	603	544	11%	13%	377	319	18%	226	225	—	6%	48	38	28%	32%	82	63	30%	38%	95	124	(23%)	(19%)
Vaccines	1,247	1,375	(9%)	(6%)	492	634	(22%)	754	741	2%	7%	250	263	(5%)	(2%)	97	102	(5%)	(4%)	407	376	8%	17%
Prevnar 13/Prevnar 13	1,116	1,179	(5%)	(2%)	481	612	(22%)	636	567	12%	18%	170	134	27%	31%	94	93	1%	2%	372	340	9%	18%
Nimenrix	56	58	(4%)	2%	—	—	—	56	58	(4%)	2%	31	31	(1%)	2%	3	8	(64%)	(60%)	22	19	18%	30%
All other Vaccines	75	138	(46%)	(44%)	12	22	(46%)	63	117	(46%)	(44%)	50	98	(49%)	(48%)	1	2	(69%)	(67%)	13	17	(24%)	(19%)
Inflammation & Immunology (I&I)	1,149	1,219	(6%)	(3%)	551	560	(2%)	597	659	(9%)	(5%)	274	341	(20%)	(17%)	156	151	4%	4%	168	167	—	11%
Xeljanz	635	613	4%	5%	458	458	—	177	155	14%	20%	63	64	(1%)	2%	63	50	26%	28%	51	41	24%	39%
Enbrel (Outside the U.S. and Canada)	337	420	(20%)	(16%)	—	—	—	337	420	(20%)	(16%)	159	217	(27%)	(24%)	66	82	(19%)	(18%)	112	121	(8%)	1%
Inflectra/Remsima ^(c)	150	153	(2%)	1%	72	74	(3%)	78	78	—	5%	57	66	(14%)	(12%)	16	7	*	*	5	5	5%	27%
All other I&I	26	34	(23%)	(25%)	21	27	(23%)	5	6	(24%)	(31%)	(5)	(6)	3%	1%	10	12	(14%)	(16%)	—	—	—	—
Rare Disease	681	521	31%	34%	277	149	86%	404	372	8%	13%	186	185	—	4%	138	93	48%	47%	80	94	(15%)	(4%)
Vyndaqel/Vyndamax	277	63	*	*	145	8	*	131	55	*	*	54	34	60%	65%	72	17	*	*	5	4	24%	36%
BeneFIX	109	121	(10%)	(8%)	56	59	(5%)	53	62	(16%)	(11%)	18	25	(29%)	(27%)	17	18	(9%)	(6%)	18	18	(4%)	6%
Genotropin	106	125	(15%)	(12%)	24	21	15%	82	104	(22%)	(18%)	35	41	(16%)	(13%)	31	39	(21%)	(22%)	16	24	(33%)	(21%)
Refacto AF/Xyntha	91	108	(16%)	(12%)	18	22	(17%)	73	87	(16%)	(11%)	41	50	(17%)	(14%)	9	10	(13%)	(5%)	23	27	(16%)	(8%)
Somavert	67	68	(2%)	1%	25	29	(13%)	43	40	7%	11%	33	32	4%	8%	6	5	19%	20%	4	3	10%	24%
All other Rare Disease	31	35	(13%)	(5%)	8	11	(25%)	23	25	(8%)	4%	5	4	31%	38%	4	5	(7%)	(1%)	14	16	(17%)	(1%)
UPJOHN^(b)	2,006	2,970	(32%)	(31%)	357	1,245	(71%)	1,648	1,725	(4%)	(2%)	223	243	(8%)	(5%)	563	631	(11%)	(12%)	862	851	1%	7%
Lipitor	431	407	6%	10%	43	30	44%	388	377	3%	7%	37	42	(12%)	(9%)	46	52	(11%)	(8%)	305	284	8%	13%
Lyrica	349	1,175	(70%)	(70%)	51	835	(94%)	298	340	(13%)	(12%)	38	53	(27%)	(25%)	203	213	(5%)	(7%)	56	75	(25%)	(21%)
Norvasc	222	216	3%	7%	7	11	(32%)	215	205	5%	9%	16	15	6%	9%	39	46	(15%)	(15%)	160	145	11%	16%
Celebrex	139	174	(20%)	(18%)	10	16	(33%)	129	158	(18%)	(17%)	5	6	(18%)	(16%)	56	83	(32%)	(33%)	68	69	(2%)	3%
Viagra	94	114	(18%)	(15%)	11	13	(15%)																

Pfizer Inc. Revenues
First Quarter 2020 and 2019
Unaudited
(millions of dollars)
Quarter-to-Date

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL ^(a)				DEVELOPED EUROPE ^(b)				DEVELOPED REST OF WORLD ^(b)				EMERGING MARKETS ^(b)			
			% of Change				% of Change			% of Change				% of Change				% of Change				% of Change	
	2020	2019	Reported	Operational	2020	2019	Reported	2020	2019	Reported	Operational	2020	2019	Reported	Operational	2020	2019	Reported	Operational	2020	2019	Reported	Operational
TOTAL REVENUES	12,028	13,118	(8%)	(7%)	5,651	6,175	(8%)	6,377	6,943	(8%)	(6%)	1,921	2,086	(8%)	(6%)	1,456	1,535	(5%)	(5%)	3,001	3,322	(10%)	(7%)
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)	10,007	9,045	11%	12%	5,213	4,461	17%	4,793	4,584	5%	7%	1,708	1,762	(3%)	(1%)	919	878	5%	5%	2,166	1,944	11%	15%
Internal Medicine^(c)	2,332	2,137	9%	10%	1,348	1,181	14%	984	956	3%	5%	455	428	6%	9%	212	212	—	—	317	316	—	4%
Eliquis alliance revenues and direct sales	1,300	1,011	29%	29%	805	601	34%	495	410	21%	23%	278	239	16%	19%	87	79	10%	10%	130	92	42%	44%
Chantix/Champix	270	273	(1%)	—	212	212	—	59	61	(3%)	(1%)	34	20	68%	72%	15	17	(13%)	(11%)	10	24	(57%)	(56%)
Premarin family	152	168	(10%)	(10%)	141	158	(10%)	10	10	1%	1%	—	—	—	—	5	5	1%	1%	5	5	1%	2%
BMP2	69	67	4%	4%	69	67	4%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Toviaz	60	60	—	—	19	17	13%	41	43	(5%)	(5%)	16	17	(6%)	(4%)	22	24	(7%)	(8%)	3	3	12%	17%
All other Internal Medicine	480	559	(14%)	(12%)	102	127	(20%)	378	432	(12%)	(10%)	127	152	(16%)	(14%)	83	87	(5%)	(5%)	168	193	(13%)	(8%)
Oncology	2,435	1,961	24%	25%	1,572	1,179	33%	863	782	10%	14%	365	393	(7%)	(5%)	167	153	9%	9%	332	236	41%	48%
Ibrance	1,248	1,133	10%	11%	852	741	15%	396	392	1%	5%	197	228	(13%)	(11%)	85	74	15%	14%	114	90	27%	37%
Xtandi alliance revenues	209	168	25%	25%	209	168	25%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Sutent	205	232	(12%)	(9%)	52	71	(27%)	153	161	(5%)	(2%)	61	76	(19%)	(17%)	21	26	(18%)	(18%)	71	59	19%	25%
Inlyta	169	73	*	*	116	33	*	53	40	32%	36%	14	9	63%	67%	16	17	(6%)	(7%)	23	15	58%	65%
Xalkori	149	123	22%	24%	39	34	14%	110	88	24%	27%	23	29	(22%)	(20%)	11	13	(17%)	(16%)	76	46	65%	69%
Bosulfif	100	80	24%	24%	68	54	26%	32	27	21%	21%	15	15	3%	5%	11	10	13%	11%	6	2	*	*
Retacrit ^(c)	89	31	*	*	66	14	*	23	17	37%	42%	22	16	36%	40%	—	—	—	—	—	—	—	—
Braftovi	37	—	*	*	37	—	*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Mektovi	37	—	*	*	37	—	*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
All other Oncology	192	122	57%	58%	96	65	49%	95	57	66%	69%	31	20	54%	57%	23	13	70%	69%	42	24	75%	78%
Hospital^{(a)(d)}	2,012	1,827	10%	11%	814	692	18%	1,198	1,135	6%	7%	207	219	(5%)	(3%)	168	184	(9%)	(8%)	822	732	12%	14%
Sulperazon	187	177	6%	8%	—	—	—	187	177	6%	8%	—	—	—	—	2	2	1%	(1%)	185	175	6%	8%
Zithromax	138	104	32%	34%	3	(3)	*	136	107	26%	28%	15	15	—	3%	9	10	(18%)	(18%)	112	82	37%	39%
Medrol	129	120	8%	8%	78	70	10%	51	50	4%	4%	15	17	(11%)	(9%)	10	8	33%	31%	26	25	4%	5%
Vlend	74	85	(12%)	(11%)	1	4	(68%)	73	81	(9%)	(8%)	4	6	(21%)	(19%)	15	18	(15%)	(16%)	54	57	(7%)	(5%)
Panzylga	74	17	*	*	74	17	*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Zyvoz	70	64	11%	12%	6	5	20%	64	58	10%	12%	2	3	(29%)	(27%)	6	13	(53%)	(53%)	56	42	33%	35%
Fragmin	59	60	(1%)	—	2	2	6%	57	58	(1%)	—	29	29	(1%)	—	13	14	(8%)	(9%)	16	15	4%	7%
Pfizer CentreOne ^(d)	152	176	(13%)	(13%)	76	97	(21%)	76	79	(4%)	(2%)	37	37	(2%)	—	5	3	*	*	34	39	(13%)	(12%)
All other Anti-infectives	444	405	10%	11%	136	128	6%	308	277	11%	13%	71	71	—	3%	24	27	(9%)	(9%)	213	179	18%	21%
All other Hospital ^(d)	684	620	10%	11%	438	371	18%	246	249	(1%)	—	34	42	(17%)	(16%)	84	90	(7%)	(6%)	128	118	9%	10%
Vaccines	1,611	1,612	—	1%	812	894	(9%)	799	718	11%	14%	250	226	10%	13%	103	92	13%	14%	446	400	11%	15%
Prevnar 13/Prevnar 13	1,450	1,486	(2%)	(1%)	794	878	(10%)	656	608	8%	11%	149	143	4%	6%	97	86	13%	14%	410	379	8%	12%
Nimenrix	75	50	50%	54%	—	—	—	75	50	50%	54%	40	29	36%	39%	5	5	11%	15%	29	15	91%	96%
All other Vaccines	86	77	13%	15%	18	17	7%	69	60	14%	17%	61	54	14%	17%	1	1	(24%)	(25%)	6	5	26%	30%
Inflammation & Immunology (I&I)	978	1,037	(6%)	(4%)	391	378	3%	587	659	(11%)	(8%)	270	325	(17%)	(15%)	149	151	(2%)	(2%)	168	182	(8%)	(1%)
Xeljanz	451	423	7%	8%	286	298	(4%)	166	125	33%	38%	66	45	45%	48%	54	43	26%	26%	45	36	27%	39%
Enbrel (Outside the U.S. and Canada)	347	451	(23%)	(21%)	—	—	—	347	451	(23%)	(21%)	154	217	(29%)	(27%)	75	93	(19%)	(18%)	117	141	(17%)	(12%)
Inflectra/Remsima ^(c)	158	138	14%	15%	84	57	46%	74	81	(8%)	(6%)	59	71	(16%)	(14%)	10	5	84%	84%	5	5	3%	10%
All other I&I	22	25	(12%)	(13%)	21	22	(4%)	1	3	(70%)	(82%)	(9)	(7)	(18%)	(22%)	9	10	(10%)	(11%)	—	—	—	—
Rare Disease	639	470	36%	38%	277	137	*	362	333	9%	12%	161	170	(5%)	(3%)	120	86	40%	40%	81	78	5%	11%
Vyndaqel/Vyndamax	231	41	*	*	127	—	*	105	41	*	*	38	25	53%	57%	61	12	*	*	6	4	37%	46%
BeneFIX	121	125	(3%)	(2%)	66	65	1%	55	60	(8%)	(4%)	20	26	(23%)	(21%)	17	19	(12%)	(10%)	19	15	24%	32%
Genotopin	103	107	(4%)	(3%)	31	13	*	72	95	(24%)	(22%)	32	38	(17%)	(15%)	25	36	(31%)	(32%)	16	21	(25%)	(19%)
Refacto AF/Xyntha	89	106	(16%)	(14%)	19	27	(31%)	71	79	(10%)	(8%)	39	46	(15%)	(13%)	9	11	(21%)	(18%)	23	22	5%	9%
Somavert	64	59	7%	9%	25	22	17%	38	38	1%	4%	30	31	(3%)	—	5	4	18%	17%	4	3	19%	30%
All other Rare Disease	31	31	—	5%	9	10	(6%)	21	20	4%	11%	3	4	(36%)	(36%)	5	4	15%	16%	14	12	14%	26%
UPJOHN^(d)	2,022	3,214	(37%)	(37%)	438	1,273	(66%)	1,584	1,941	(18%)	(17%)	213	217	(2%)	—	537	572	(6%)	(6%)	834	1,152	(28%)	(26%)
Lipitor	405	622	(35%)	(34%)	25	21	17%	380	601	(37%)	(35%)	35	38	(6%)	(4%)	43	50	(14%)	(11%)	302	513	(41%)	(40%)
Lyrice	357	1,186	(70%)	(70%)	80	889	(91%)	277	298	(7%)	(7%)	39	45	(14%)	(12%)	183	189	(3%)	(3%)	54	63	(14%)	(13%)
Norvasc	197	300	(34%)	(33%)	9	10	(13%)	188	289	(35%)	(34%)	13	15	(11%)	(8%)	36	41	(12%)	(11%)	139	234	(41%)	(39%)
Celebrex	156	174	(10%)	(10%)	11	15	(23%)	145	159	(9%)	(9%)	5	6	(6%)	(4%)	75	71	6%	5%	64	82	(22%)	(21%)
Viagra	127	145	(12%)	(12%)	17	40	(57%)	110	105	5%	5%	17	8	*	*	15	15	(2%)	(2%)	78	82	(5%)	(4%)
Zolof	78	69	13%	15%	12	11	7%	66	58	14%													

Pfizer Inc. Revenues
 Twelve Months 2019 and 2018
 Meridian & Mylan-Japan Reclassified to Upjohn – Unaudited
 (millions of dollars)
 Year-to-Date

	WORLDWIDE				UNITED STATES				TOTAL INTERNATIONAL ^(a)				DEVELOPED EUROPE ^(a)				DEVELOPED REST OF WORLD ^(a)				EMERGING MARKETS ^(a)				
	2019		2018		2019		2018		2019		2018		2019		2018		2019		2018		2019		2018		
	Reported	% of Change	Operational	% of Change	Reported	% of Change	Operational	% of Change	Reported	% of Change	Operational	% of Change	Reported	% of Change	Operational	% of Change	Reported	% of Change	Operational	% of Change	Reported	% of Change	Operational	% of Change	
TOTAL REVENUES	51,750	53,647	(4%)	(1%)	23,852	25,329	(6%)	(6%)	27,898	28,318	(1%)	3%	8,701	9,116	(5%)	1%	6,465	6,551	(1%)	(0%)	12,733	12,651	1%	7%	
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)^(b)	38,823	36,965	5%	8%	19,338	17,971	8%	(8%)	19,485	18,993	3%	8%	7,444	7,540	(1%)	4%	3,808	3,758	1%	3%	8,234	7,995	7%	14%	
Internal Medicine ^(c)	8,790	8,548	3%	5%	4,764	4,542	5%	(5%)	4,025	4,006	—	6%	1,777	1,707	4%	10%	941	991	(5%)	(4%)	1,308	1,308	—	7%	
Eliquis alliance revenues and direct sales	4,220	3,434	23%	26%	2,343	1,849	27%	(27%)	1,877	1,585	18%	24%	1,089	947	15%	21%	367	333	10%	11%	421	304	38%	47%	
Chantix/Champix	1,107	1,085	2%	3%	899	838	7%	(7%)	208	247	(16%)	(12%)	80	83	(4%)	2%	71	111	(36%)	(34%)	57	52	9%	14%	
Premarin family	734	832	(12%)	(12%)	690	783	(12%)	(6%)	44	49	(10%)	(6%)	2	2	(7%)	(2%)	21	23	(9%)	(7%)	22	24	(10%)	(5%)	
BMP2	287	279	3%	3%	287	278	3%	(3%)	—	1	—	(100%)	—	0	—	(100%)	—	—	—	—	—	—	1	—	(100%)
Toviaz	250	271	(8%)	(6%)	70	87	(20%)	(1%)	180	183	(2%)	1%	67	71	(6%)	(1%)	101	101	1%	1%	11	11	2%	16%	
All other Internal Medicine	2,192	2,648	(17%)	(14%)	476	707	(33%)	(7%)	1,716	1,941	(12%)	(7%)	539	603	(11%)	(6%)	380	423	(10%)	(9%)	797	916	(13%)	(6%)	
Oncology ^(d)	9,014	7,471	21%	23%	5,591	4,657	20%	(22%)	3,422	2,814	22%	29%	1,667	1,436	16%	23%	674	573	18%	16%	1,081	806	34%	49%	
Ibrance	4,961	4,118	20%	23%	3,250	2,922	11%	(11%)	1,710	1,196	43%	53%	992	725	36%	43%	336	245	37%	38%	391	226	56%	73%	
Sutent	936	1,049	(11%)	(7%)	283	357	(21%)	(5%)	653	692	(6%)	1%	284	323	(12%)	(7%)	102	119	(14%)	(12%)	266	250	7%	17%	
Xtandi alliance revenues	838	699	20%	20%	838	699	20%	(20%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
Xalkori	530	524	1%	5%	149	158	(5%)	(9%)	381	366	4%	9%	113	154	(26%)	(22%)	49	58	(15%)	(14%)	219	154	42%	50%	
Inlyta	477	298	60%	64%	295	119	*	(64%)	182	178	2%	8%	40	48	(16%)	(11%)	71	77	(8%)	(9%)	70	53	33%	50%	
Bosulif	365	296	23%	25%	243	196	24%	(24%)	122	99	23%	26%	62	52	18%	25%	47	39	19%	18%	13	8	71%	77%	
Retacrit ^(e)	225	82	*	*	141	6	*	(96%)	85	76	11%	17%	83	70	19%	25%	—	—	—	—	2	6	(74%)	(72%)	
Mektovi	49	—	*	*	49	—	*	(100%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
Braftovi	48	—	*	*	48	—	*	(100%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
All other Oncology	585	406	44%	47%	295	199	48%	(48%)	290	207	40%	45%	102	64	58%	66%	68	34	*	*	120	108	11%	16%	
Hospital ^(f)	7,505	7,882	(2%)	0%	2,814	2,836	(1%)	(1%)	4,691	4,846	(3%)	1%	897	1,015	(12%)	(7%)	758	829	(9%)	(6%)	3,036	3,002	1%	6%	
Sulperazon	684	613	12%	17%	—	—	—	—	684	613	12%	17%	—	—	—	—	9	10	(6%)	(7%)	675	603	12%	17%	
Medrol ^(g)	469	493	(5%)	(3%)	248	266	(7%)	(3%)	221	227	(3%)	1%	67	74	(9%)	(4%)	43	26	64%	(65%)	111	127	(12%)	(9%)	
Vlend	346	392	(12%)	(8%)	13	10	24%	(24%)	333	382	(13%)	(9%)	21	36	(42%)	(39%)	72	80	(10%)	(10%)	240	267	(10%)	(4%)	
Zithromax ^(h)	336	326	3%	7%	(1)	7	*	(100%)	338	319	6%	10%	49	52	(7%)	(1%)	39	41	(5%)	(5%)	250	226	10%	15%	
Fragmin	253	293	(14%)	(9%)	9	14	(33%)	(33%)	244	279	(13%)	(8%)	116	143	(18%)	(14%)	63	75	(17%)	(14%)	65	61	6%	12%	
Zyvox	251	236	7%	10%	27	(3)	*	(100%)	225	239	(6%)	(3%)	12	15	(18%)	(13%)	46	55	(17%)	(17%)	167	169	(1%)	3%	
Zosyn/Tazocin	200	230	(13%)	(11%)	131	151	(13%)	(8%)	69	79	(13%)	(8%)	2	5	(65%)	(64%)	3	5	(31%)	(28%)	64	70	(9%)	(3%)	
Tyagcil	197	249	(21%)	(17%)	15	25	(42%)	(42%)	182	223	(18%)	(15%)	29	66	(56%)	(53%)	5	6	(7%)	(2%)	148	151	(3%)	2%	
Diflucan	180	189	1%	5%	2	2	(11%)	(11%)	188	186	1%	5%	32	35	(9%)	(4%)	11	11	(6%)	(4%)	145	140	4%	8%	
Panzaya	183	39	*	*	183	39	*	(100%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
Pfizer CentreOne ⁽ⁱ⁾	810	755	7%	9%	437	409	7%	(7%)	374	345	8%	12%	162	138	18%	21%	17	15	12%	12%	194	192	1%	5%	
All other Anti-infectives	1,114	1,041	7%	11%	341	296	15%	(15%)	773	745	4%	7%	242	239	1%	7%	94	95	(1%)	(0%)	437	411	6%	13%	
All other Hospital ^(j)	2,473	2,828	(13%)	(11%)	1,411	1,619	(13%)	(13%)	1,062	1,209	(12%)	(8%)	165	213	(23%)	(18%)	357	411	(13%)	(10%)	540	584	(6%)	(4%)	
Vaccines	6,594	6,332	3%	5%	3,331	3,469	(4%)	(4%)	3,173	2,863	11%	16%	1,041	974	7%	13%	403	420	(4%)	(2%)	1,728	1,469	18%	22%	
Prevnar 13/Prevenar 13	5,947	5,802	1%	3%	3,209	3,360	(4%)	(4%)	2,638	2,443	8%	12%	650	655	(1%)	4%	377	402	(6%)	(5%)	1,611	1,386	16%	21%	
Nimenrix	230	140	65%	75%	—	—	—	—	230	140	65%	75%	129	80	60%	69%	21	15	39%	49%	80	44	82%	93%	
FSME/IMMUN-TicoVac	220	184	20%	27%	—	—	—	—	220	184	20%	27%	190	158	20%	27%	0	0	*	*	29	25	17%	25%	
Trumenba	135	116	16%	17%	122	109	11%	(11%)	13	7	92%	*	11	6	96%	*	0	0	97%	*	2	1	68%	77%	
All other Vaccines	73	90	(19%)	(15%)	0	(0)	*	(100%)	73	90	(19%)	(15%)	62	74	(17%)	(12%)	5	3	68%	73%	6	13	(56%)	(54%)	
Inflammation & Immunology (I&I) ^(k)	4,733	4,720	—	4%	2,077	1,816	14%	(14%)	2,655	2,904	(9%)	(2%)	1,323	1,574	(16%)	(11%)	618	577	7%	9%	714	753	(5%)	8%	
Xeljanz	2,242	1,774	26%	29%	1,636	1,394	17%	(17%)	606	380	59%	70%	241	121	99%	*	211	148	42%	44%	154	110	40%	63%	
Embrel (Outside the U.S. and Canada)	1,699	2,112	(20%)	(14%)	—	—	—	—	1,699	2,112	(20%)	(14%)	828	1,152	(28%)	(24%)	332	358	(7%)	(6%)	539	603	(10%)	1%	
Infectra/Remsimva ^(l)	625	642	(3%)	0%	300	259	16%	(16%)	325	383	(15%)	(10%)	273	319	(14%)	(10%)	32	24	31%	36%	21	40	(49%)	(45%)	
Eucrisa	138	147	(7%)	(7%)	134	147	(9%)	(9%)	3	0	*	*	0	—	*	*	3	0	*	*	0	0	*	*	
All other I&I	29	45	(34%)	(37%)	8	16	(53%)	(53%)	22	28	(23%)	(28%)	(19)	(18)	8%	14%	41	46	(11%)	(12%)	0	0	*	*	
Rare Disease	2,278	2,211	3%	7%	760	652	17%	(17%)	1,518	1,560	(3%)	3%	739	835	(11%)	(6%)	413	368	12%	13%	366	357	3%	15%	
Genotropin	498	558	(11%)	(7%)	93	130	(29%)	(29%)	405	428	(5%)	(1%)	156	179	(13%)	(8%)	153	156	(2%)	(2%)	96	92	4%	16%	
BeneFIX	488	554	(12%)	(9%)	242	245	(1%)	(1%)	246	309	(20%)	(15%)	98	153	(36%)	(32%)	72	82	(12%)	(9%)	76	74	3%	14%	
Vyndaqel/Vyndamax	473	148	*	*	191	—	*	(100%)	282	148	91%	96%	152	92	65%	74%	109	43	*	*	21	13	63%	81%	
Refacto AF/Xyntha	426	514	(17%)	(12%)	92	109	(15%)	(15%)	333	404	(18%)	(11%)	192	245	(22%)	(17%)	40	48	(17%)	(12%)	102	111	(8%)	4%	
Somavert	264	267	(1%)	3%	105	103	2%	(2%)	159	164	(3%)	3%	125	130	(4%)	2%	20	20	—	1%	14	14	2%	17%	
All other Rare Disease	129	170	(24%)	(18%)	37	64	(43%)	(43%)	92	106	(13%)	(3%)	16	34	(54%)	(52%)	19	19	1%						

Pfizer Inc. Revenues
Twelve Months 2019 and 2018
Unaudited
(millions of dollars)
Year-to-Date

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL ^(a)				DEVELOPED EUROPE ^(a)				DEVELOPED REST OF WORLD ^(a)				EMERGING MARKETS ^(a)				
			% of Change				% of Change				% of Change				% of Change				% of Change					
	2019	2018	Reported	Operational	2019	2018	Reported	2019	2018	Reported	Operational	2019	2018	Reported	Operational	2019	2018	Reported	Operational	2019	2018	Reported	Operational	
TOTAL REVENUES	51,750	53,647	(4%)	(1%)	23,852	25,329	(6%)	27,898	28,318	(1%)	3%	8,701	9,116	(5%)	1%	6,465	6,551	(1%)	—	12,733	12,651	1%	7%	
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)^(b)	39,419	37,558	5%	8%	19,605	18,243	7%	19,814	19,315	3%	8%	7,444	7,540	(1%)	4%	4,137	4,080	1%	3%	8,234	7,695	7%	14%	
Internal Medicine^(c)	9,119	8,869	3%	5%	4,764	4,542	5%	4,355	4,327	1%	5%	1,777	1,707	4%	10%	1,270	1,312	(3%)	(2%)	1,308	1,308	—	7%	
Eliquis alliance revenues and direct sales	4,220	3,434	23%	26%	2,343	1,849	27%	1,877	1,585	18%	24%	1,089	947	15%	21%	367	333	10%	11%	421	304	38%	47%	
Chantix/Champix	1,107	1,085	2%	3%	899	838	7%	208	247	(16%)	(12%)	80	83	(4%)	2%	71	111	(36%)	(34%)	57	52	9%	14%	
Premarin Family	734	832	(12%)	(12%)	690	783	(12%)	44	49	(10%)	(6%)	2	2	(7%)	(2%)	21	23	(9%)	(7%)	22	24	(10%)	(5%)	
BMP2	267	279	3%	3%	267	278	3%	—	1	*	*	—	—	—	—	—	—	—	—	—	—	—	—	
Toviaz	250	271	(8%)	(6%)	70	87	(20%)	180	183	(2%)	1%	67	71	(6%)	(1%)	101	101	1%	1%	11	11	2%	16%	
All other Internal Medicine	2,521	2,969	(15%)	(12%)	476	707	(33%)	2,045	2,262	(10%)	(5%)	539	603	(11%)	(6%)	709	743	(5%)	(4%)	797	916	(13%)	(6%)	
Oncology^(d)	9,014	7,471	21%	23%	5,591	4,657	20%	3,422	2,814	22%	23%	1,667	1,436	16%	23%	674	573	18%	18%	1,081	806	34%	49%	
Ibrance	4,961	4,118	20%	23%	3,250	2,922	11%	1,710	1,196	43%	53%	982	725	36%	43%	336	245	37%	38%	391	226	73%	*	
Sutent	936	1,049	(11%)	(7%)	283	357	(21%)	653	692	(6%)	1%	284	323	(12%)	(7%)	102	119	(14%)	(12%)	266	250	7%	17%	
Xtandi alliance revenues	838	699	20%	20%	838	699	20%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
Xalkori	530	524	1%	5%	149	158	(5%)	381	366	4%	9%	113	154	(26%)	(22%)	49	58	(15%)	(14%)	219	154	42%	50%	
Inlyta	477	298	60%	64%	295	119	*	182	178	2%	8%	40	48	(16%)	(11%)	71	77	(8%)	(9%)	70	53	33%	50%	
Bosulif	365	296	23%	25%	243	196	24%	122	99	23%	26%	62	52	18%	25%	13	8	71%	18%	13	8	71%	77%	
Retacrit ^(e)	225	82	*	*	141	6	*	85	76	11%	17%	83	70	19%	25%	—	—	—	—	2	6	(74%)	(72%)	
Mektovi	49	—	*	*	49	—	*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
Braftovi	48	—	*	*	48	—	*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
All other Oncology	585	406	44%	47%	295	199	48%	290	207	40%	45%	102	64	58%	66%	68	34	*	*	120	108	11%	16%	
Hospital^(f)	7,772	7,955	(2%)	—	3,081	3,107	(1%)	4,691	4,848	(3%)	1%	897	1,015	(12%)	(7%)	758	830	(9%)	(7%)	3,036	3,002	1%	6%	
Sulperazon	684	613	12%	17%	—	—	—	684	613	12%	17%	—	—	—	—	9	10	(6%)	(7%)	675	603	12%	17%	
Medrol ^(g)	469	493	(5%)	(3%)	248	266	(7%)	221	227	(3%)	1%	67	74	(9%)	(4%)	43	26	64%	65%	111	127	(12%)	(9%)	
Vlend	346	392	(12%)	(8%)	13	10	(24%)	333	382	(13%)	(9%)	21	36	(42%)	(39%)	72	80	(10%)	(10%)	240	267	(10%)	(4%)	
Zithromax ^(h)	336	326	3%	7%	(1)	7	*	338	319	6%	10%	49	52	(7%)	(1%)	39	41	(5%)	(5%)	250	226	10%	15%	
EpiPen	303	303	—	—	248	242	3%	55	62	(11%)	(9%)	—	—	—	—	55	62	(11%)	(9%)	—	—	—	—	
Fragmin	253	293	(14%)	(9%)	9	14	(33%)	244	279	(13%)	(8%)	116	143	(18%)	(14%)	63	75	(17%)	(14%)	65	61	8%	12%	
Zyvox	251	236	7%	10%	27	(3)	*	225	239	(6%)	(3%)	12	15	(18%)	(13%)	46	55	(17%)	(17%)	167	169	(1%)	3%	
Zosyn/Tazocin	200	230	(13%)	(11%)	131	151	(13%)	69	79	(13%)	(8%)	2	5	(65%)	(64%)	3	5	(31%)	(28%)	64	70	(9%)	(3%)	
Tygacil	197	249	(21%)	(17%)	15	25	(42%)	182	223	(18%)	(15%)	29	66	(56%)	(53%)	5	6	(7%)	(2%)	148	151	(3%)	2%	
Diflucan	190	189	1%	5%	2	2	(11%)	188	186	1%	5%	32	35	(9%)	(4%)	11	11	(6%)	(4%)	145	140	4%	8%	
Panzyga	163	39	*	*	163	39	*	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
Pfizer CentraOne ⁽ⁱ⁾	810	755	7%	9%	437	409	7%	374	345	8%	12%	162	138	18%	21%	12	15	12%	13%	194	192	1%	5%	
All other Anti-infectives	1,114	1,041	7%	11%	341	296	15%	773	745	4%	9%	242	239	1%	7%	94	95	(1%)	—	437	411	6%	13%	
All other Hospital ^(j)	2,436	2,797	(13%)	(11%)	1,429	1,649	(13%)	1,007	1,148	(12%)	(9%)	162	213	(23%)	(18%)	302	350	(14%)	(10%)	540	584	(8%)	(4%)	
Vaccines	6,504	6,332	3%	5%	3,331	3,469	(4%)	3,173	2,863	11%	16%	1,041	974	7%	13%	403	420	(4%)	(2%)	1,728	1,469	18%	22%	
Prevnar 13/Prevnar 13	5,847	5,802	1%	3%	3,209	3,360	(4%)	2,638	2,443	8%	12%	650	655	(1%)	4%	377	402	(6%)	(5%)	1,611	1,386	16%	21%	
Nimenrix	230	140	65%	75%	—	—	—	230	140	65%	75%	129	80	60%	69%	21	15	39%	49%	80	44	82%	93%	
FSME/IMMUN-TicoVac	220	184	20%	27%	—	—	—	220	184	20%	27%	190	158	20%	27%	21	—	—	—	29	25	17%	25%	
Trumenba	135	116	16%	17%	122	109	11%	13	7	92%	(5%)	11	6	96%	*	—	—	—	—	2	1	68%	77%	
All other Vaccines	73	90	(19%)	(15%)	—	—	—	73	90	(19%)	(15%)	62	74	(17%)	(12%)	5	3	68%	73%	6	13	(56%)	(54%)	
Inflammation & Immunology (I&I)^(k)	4,733	4,720	—	4%	2,077	1,816	14%	2,655	2,904	(9%)	(2%)	1,323	1,574	(16%)	(11%)	618	577	7%	9%	714	753	(5%)	8%	
Xeljanz	2,242	1,774	26%	29%	1,636	1,394	17%	606	380	59%	70%	241	121	99%	(*)	211	148	42%	44%	154	110	40%	63%	
Enbrel (Outside the U.S. and Canada)	1,699	2,112	(20%)	(14%)	—	—	—	1,699	2,112	(20%)	(14%)	828	1,152	(28%)	(24%)	332	358	(7%)	(6%)	539	603	(10%)	1%	
Inflectra/Remsima ^(l)	625	642	(3%)	—	300	259	16%	325	383	(15%)	(10%)	273	319	(14%)	(10%)	32	24	31%	36%	21	40	(49%)	(45%)	
Eucrisa	138	147	(7%)	(7%)	134	147	(9%)	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
All other I&I	29	45	(34%)	(37%)	8	16	(53%)	22	28	(23%)	(28%)	(19)	(18)	(8%)	(14%)	3	41	46	(11%)	(12%)	—	—	—	—
Rare Disease	2,278	2,211	3%	7%	760	652	17%	1,518	1,560	(3%)	3%	739	835	(11%)	(6%)	413	368	12%	13%	366	357	3%	15%	
Genotropin	498	558	(11%)	(7%)	93	130	(29%)	405	428	(5%)	(1%)	156	179	(13%)	(8%)	153	156	(2%)	(2%)	96	92	4%	16%	
BeneFIX	488	554	(12%)	(9%)	242	245	(1%)	246	309	(20%)	(15%)	98	153	(36%)	(32%)	72	82	(12%)	(9%)	76	74	3%	14%	
Vyndaqel/Vyndamax	473	148	*	*	191	—	*	282	148	91%	96%	152	92	65%	74%	109	43	*	*	21	13	63%	81%	
Refacto AF/Xyntha	426	514	(17%)	(12%)	92	109	(15%)	333	404	(18%)	(11%)	192	245	(22%)	(17%)	40	48	(17%)						

Pfizer Inc. Revenues
Fourth Quarter 2019 and 2018
Unaudited
(millions of dollars)
Quarter-to-Date

	WORLDWIDE				UNITED STATES				TOTAL INTERNATIONAL ^(a)				DEVELOPED EUROPE ^(a)				DEVELOPED REST OF WORLD ^(a)				EMERGING MARKETS ^(a)			
			% of Change				% of Change				% of Change				% of Change				% of Change					
	2019	2018	Reported	Operational	2019	2018	Reported		2019	2018	Reported	Operational	2019	2018	Reported	Operational	2019	2018	Reported	Operational	2019	2018	Reported	Operational
TOTAL REVENUES	12,688	13,976	(9%)	(8%)	5,491	6,468	(15%)		7,197	7,508	(4%)	(2%)	2,251	2,459	(8%)	(5%)	1,706	1,755	(3%)	(4%)	3,240	3,294	(2%)	1%
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)^(b)	10,532	9,820	7%	9%	5,124	4,661	10%		5,409	5,160	5%	8%	1,987	2,031	(2%)	2%	1,128	1,087	4%	2%	2,293	2,041	12%	16%
Internal Medicine^(c)	2,365	2,340	1%	2%	1,195	1,187	1%		1,170	1,153	1%	3%	489	461	6%	11%	344	350	(2%)	(4%)	337	342	(2%)	1%
Eliquis alliance revenues and direct sales	1,099	910	21%	22%	575	478	20%		524	432	21%	24%	303	256	19%	24%	107	93	14%	13%	114	83	37%	40%
Chantix/Champix	282	296	(5%)	(4%)	233	236	(1%)		49	59	(18%)	(16%)	20	23	(11%)	(7%)	18	26	(33%)	(32%)	11	10	4%	3%
Premarin family	192	227	(16%)	(16%)	179	214	(16%)		12	13	(8%)	(6%)	—	—	—	—	6	6	(3%)	(2%)	6	6	(12%)	(10%)
BMP2	75	72	4%	4%	75	71	6%		—	1	*	*	—	—	—	—	—	—	—	—	—	1	*	*
Toviaz	64	74	(14%)	(14%)	15	25	(38%)		48	49	(1%)	(1%)	17	19	(8%)	(4%)	28	27	2%	(1%)	3	3	16%	14%
All other Internal Medicine	654	761	(14%)	(13%)	117	162	(28%)		537	599	(10%)	(9%)	148	163	(9%)	(6%)	185	197	(6%)	(8%)	204	239	(15%)	(12%)
Oncology^(d)	2,466	1,984	24%	26%	1,561	1,225	27%		906	759	19%	24%	419	408	3%	7%	187	166	13%	10%	300	185	62%	72%
Ibrance	1,283	1,133	13%	15%	846	743	14%		437	389	12%	17%	240	242	(1%)	4%	95	79	21%	19%	102	69	48%	62%
Sutent	231	264	(12%)	(10%)	66	96	(31%)		166	168	(1%)	2%	67	83	(19%)	(16%)	26	30	(15%)	(16%)	73	55	33%	40%
Xtandi alliance revenues	244	189	29%	29%	244	189	29%		—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Xalkori	145	107	36%	39%	38	40	(4%)		107	67	59%	64%	28	33	(15%)	(11%)	12	15	(18%)	(18%)	67	19	*	*
Inlyta	161	72	*	*	110	31	*		51	40	26%	29%	11	11	6%	11%	20	20	(1%)	(4%)	20	10	*	*
Bosulif	98	89	10%	10%	65	61	8%		32	28	13%	14%	16	15	6%	10%	13	11	14%	10%	3	2	52%	55%
Retacrit ^(e)	79	27	*	*	54	6	*		24	21	18%	23%	24	20	20%	26%	—	—	—	—	1	1	(39%)	(35%)
Mektovi	30	—	*	*	30	—	*		—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Braftovi	30	—	*	*	30	—	*		—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
All other Oncology	166	104	60%	61%	77	59	31%		88	45	97%	100%	32	5	*	*	22	11	92%	87%	34	29	19%	21%
Hospital^(f)	2,056	2,011	2%	3%	818	753	9%		1,238	1,258	(2%)	—	235	254	(7%)	(4%)	194	235	(17%)	(17%)	808	770	5%	7%
Sulperazon	179	149	20%	23%	—	—	—		179	149	20%	23%	—	—	—	—	3	2	12%	7%	176	147	20%	23%
Medrol ^(g)	121	124	(3%)	(2%)	61	66	(7%)		60	59	2%	3%	18	18	(5%)	(2%)	12	8	61%	58%	30	33	(8%)	(7%)
Vfend	80	98	(18%)	(17%)	2	3	(34%)		78	95	(18%)	(17%)	5	8	(39%)	(37%)	18	20	(11%)	(14%)	56	67	(18%)	(15%)
Zithromax ^(h)	82	83	(1%)	—	(1)	2	*		83	81	3%	4%	12	14	(12%)	(8%)	12	11	(5%)	(7%)	60	55	8%	9%
Epipen	65	88	(26%)	(26%)	51	67	(24%)		14	21	(33%)	(32%)	—	—	—	—	14	21	(33%)	(32%)	—	—	—	—
Fragmin	68	72	(6%)	(3%)	2	2	23%		66	70	(7%)	(4%)	31	33	(6%)	(2%)	17	20	(16%)	(15%)	17	17	2%	5%
Zyvox	56	52	8%	9%	3	(2)	*		53	54	(3%)	(2%)	2	2	37%	44%	9	15	(41%)	(43%)	42	38	10%	12%
Zosyn/Tazocin	47	54	(13%)	(12%)	29	34	(14%)		18	20	(12%)	(9%)	—	—	23%	28%	1	1	40%	(37%)	17	19	(10%)	(8%)
Tyagcil	51	62	(19%)	(17%)	3	6	(56%)		48	56	(15%)	(13%)	6	13	(55%)	(54%)	1	1	16%	22%	41	42	(3%)	(1%)
Diflucan	51	48	5%	7%	—	—	—		51	48	5%	7%	8	8	—	4%	3	3	7%	7%	39	37	6%	8%
Panznyga	76	39	93%	93%	76	39	93%		—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pfizer CentreOne ⁽ⁱ⁾	254	215	18%	19%	141	113	25%		114	102	11%	13%	46	48	(4%)	(2%)	5	5	7%	9%	62	50	25%	28%
All other Anti-infectives	292	252	16%	18%	78	63	23%		214	189	13%	16%	65	62	4%	8%	24	25	(2%)	(4%)	125	102	23%	26%
All other Hospital ^(j)	634	673	(6%)	(5%)	372	360	3%		261	313	(16%)	(15%)	42	48	(11%)	(7%)	76	102	(25%)	(24%)	143	163	(12%)	(11%)
Vaccines	1,708	1,624	5%	7%	724	780	(7%)		984	844	17%	19%	318	307	3%	8%	117	102	14%	13%	549	434	27%	29%
Prevnar 13/Prevnar 13	1,579	1,512	4%	6%	711	763	(7%)		868	749	16%	18%	241	236	2%	6%	112	98	14%	13%	515	415	24%	27%
Nimenrix	70	44	59%	64%	—	—	—		70	44	59%	64%	38	27	41%	47%	3	5	(28%)	(25%)	29	13	*	*
FSME/MMUN-Tico/Vac	23	22	4%	8%	—	—	—		23	22	4%	8%	20	19	8%	12%	—	—	—	—	3	3	(16%)	(12%)
Trumenba	17	21	(16%)	(15%)	13	17	(21%)		4	4	8%	13%	3	3	15%	20%	—	—	—	—	—	1	(40%)	(37%)
All other Vaccines	19	25	(24%)	(22%)	—	—	—		19	25	(25%)	(22%)	16	23	(31%)	(28%)	2	—	*	*	2	3	(28%)	(27%)
Inflammation & Immunology (I&I)^(k)	1,251	1,301	(4%)	(2%)	573	546	5%		677	754	(10%)	(7%)	328	394	(17%)	(13%)	154	142	9%	7%	195	218	(11%)	(4%)
Xeljanz	607	553	10%	11%	435	429	1%		172	124	39%	44%	70	46	52%	58%	63	47	33%	32%	40	31	31%	43%
Enbrel (Outside the U.S. and Canada)	414	524	(21%)	(18%)	—	—	—		414	524	(21%)	(18%)	196	271	(28%)	(25%)	70	75	(7%)	(9%)	149	177	(16%)	(10%)
Inflectra/Remsima ^{(l), (m)}	179	173	3%	5%	91	70	31%		87	103	(15%)	(12%)	71	84	(15%)	(12%)	10	8	24%	26%	6	10	(45%)	(42%)
Eucrisa	45	43	6%	6%	44	43	4%		1	—	*	*	—	—	—	—	1	—	*	*	—	—	—	—
All other I&I	5	9	(38%)	(48%)	3	5	(39%)		3	4	(38%)	(58%)	(8)	(7)	(16%)	(22%)	11	11	(4%)	(8%)	—	—	—	—
Rare Disease	686	561	22%	25%	252	170	48%		434	391	11%	14%	198	207	(4%)	—	132	92	44%	41%	104	92	13%	19%
Genotropin	142	142	(1%)	1%	36	34	4%		106	108	(2%)	—	38	46	(17%)	(13%)	41	39	4%	1%	27	23	16%	22%
BeneFIX	117	134	(13%)	(12%)	52	62	(16%)		65	73	(11%)	(8%)	22	34	(34%)	(31%)	18	18	(3%)	(1%)	25	21	20%	24%
Vyndarel/Vyndamax	213	39	*	*	104	—	*		109	39	*	*	53	25	*	*	51	12	*	*	5	3	61%	74%
Refacto AF/Xyntha	107	125	(14%)	(11%)	22	28	(23%)		86	97	(12%)	(8%)	48	58	(17%)	(13%)	10	11	(9%)	(5%)	27	28	(3%)	2%
Somavert	72	73	—	2%	31	29	6%		42	44	(5%)	(1%)	32	34	(6%)	(3%)	6	6	7%	6%	4	4	(4%)	4%
All other Rare Disease	3																							

Pfizer Inc. Revenues
Third Quarter 2019 and 2018
Unaudited
(millions of dollars)
Quarter-to-Date

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL ^(a)				DEVELOPED EUROPE ^(a)				DEVELOPED REST OF WORLD ^(a)				EMERGING MARKETS ^(a)				
	2019		2018		2019		2018		2019		2018		2019		2018		2019		2018		2019		2018	
	Reported	% of Change	Operational	% of Change	Reported	% of Change	Reported	% of Change	Reported	% of Change	Operational	% of Change	Reported	% of Change	Operational	% of Change	Reported	% of Change	Operational	% of Change	Reported	% of Change	Operational	% of Change
TOTAL REVENUES	12,680	13,298	(5%)	(3%)	5,850	6,361	(8%)	(5%)	6,830	6,937	(2%)	(2%)	2,135	2,231	(4%)	(1%)	1,585	1,640	(3%)	(4%)	3,110	3,066	1%	6%
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)^(a)	10,108	9,422	7%	9%	5,218	4,684	11%	(4%)	4,890	4,738	3%	7%	1,835	1,867	(2%)	2%	1,035	1,024	1%	1%	2,020	1,847	9%	15%
Internal Medicine^(a)	2,207	2,182	1%	3%	1,126	1,107	2%	(1%)	1,081	1,075	1%	4%	442	425	4%	8%	309	323	(4%)	(5%)	330	327	1%	6%
Eliquis alliance revenues and direct sales	1,025	870	18%	20%	541	455	19%	20%	484	416	16%	20%	282	254	11%	16%	18	85	5%	5%	113	77	47%	51%
Chantix/Champix	276	261	6%	7%	227	197	15%	15%	49	64	(22%)	(20%)	18	19	(6%)	(2%)	18	27	(35%)	(34%)	14	18	(20%)	(17%)
Premarin family	182	204	(11%)	(11%)	170	191	(11%)	(11%)	11	12	(6%)	(5%)	—	—	—	—	5	6	(11%)	(10%)	6	6	(6%)	(2%)
BMP2	66	54	24%	24%	66	54	24%	24%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Toviaz	61	67	(8%)	(7%)	18	23	(19%)	(18%)	43	44	(3%)	(1%)	16	17	(6%)	(3%)	24	24	(1%)	(2%)	3	3	5%	12%
All other Internal Medicine	597	727	(18%)	(16%)	103	188	(45%)	(46%)	493	539	(9%)	(6%)	126	135	(7%)	(3%)	172	181	(5%)	(6%)	195	224	(13%)	(7%)
Oncology^(a)	2,350	1,840	28%	30%	1,466	1,119	31%	(28%)	884	720	23%	28%	434	371	17%	21%	172	148	16%	15%	277	201	38%	48%
Ibrance	1,283	1,025	25%	27%	832	708	18%	18%	451	317	42%	48%	265	194	37%	42%	88	67	31%	29%	99	57	75%	94%
Sutent	224	248	(10%)	(7%)	64	80	(20%)	(17%)	160	168	(5%)	(—)	67	79	(15%)	(12%)	26	30	(11%)	(11%)	67	59	13%	21%
Xtandi alliance revenues	225	180	25%	25%	225	180	25%	25%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Xalkori	130	127	2%	5%	36	34	7%	7%	94	93	1%	4%	27	35	(23%)	(21%)	12	14	(15%)	(15%)	55	44	25%	30%
Inlyta	139	71	95%	98%	92	27	—	—	46	44	6%	10%	10	11	(15%)	(12%)	17	19	(12%)	(13%)	20	14	49%	62%
Bosulif	90	69	32%	32%	61	43	42%	42%	30	26	14%	15%	15	14	5%	9%	3	2	22%	19%	3	2	39%	42%
Retacrit ^(a)	64	19	—	—	42	—	—	—	22	19	14%	18%	22	18	19%	23%	—	—	—	—	1	1	(60%)	(58%)
All other Oncology	194	101	93%	95%	113	48	—	—	80	53	52%	56%	30	19	54%	60%	17	9	98%	96%	33	25	33%	38%
Hospital^(a)	1,917	1,841	4%	6%	759	705	8%	(7%)	1,157	1,136	2%	5%	211	234	(10%)	(6%)	197	200	(1%)	(—)	749	702	7%	10%
Sulperazon	163	145	12%	16%	—	—	—	—	163	145	12%	16%	—	—	—	—	2	2	(8%)	(11%)	161	143	12%	17%
Medrol ^(a)	109	110	(1%)	—	54	55	(2%)	(—)	55	55	(1%)	1%	16	18	(9%)	(5%)	11	6	68%	67%	28	31	(10%)	(8%)
Vfend	87	87	1%	4%	3	3	(3%)	(—)	84	83	1%	4%	5	8	(35%)	(33%)	17	18	(6%)	(8%)	61	57	8%	13%
Zithromax ^(a)	77	61	25%	29%	2	—	—	—	75	61	23%	26%	10	9	3%	7%	8	9	(6%)	(6%)	57	43	33%	37%
EpiPen	92	68	36%	36%	74	55	35%	36%	18	13	36%	37%	—	—	—	—	18	13	36%	37%	—	—	—	—
Zyvox	61	50	21%	24%	5	(3)	—	—	56	53	4%	7%	4	3	21%	26%	10	14	(24%)	(25%)	42	37	14%	17%
Fragmin	62	76	(18%)	(15%)	3	4	(38%)	(34%)	60	72	(17%)	(14%)	27	35	(23%)	(19%)	15	18	(17%)	(16%)	17	19	(6%)	(2%)
Zosyn/Tazocin	49	56	(13%)	(12%)	32	35	(7%)	(6%)	16	21	(22%)	(19%)	—	1	(51%)	(49%)	1	1	(30%)	(26%)	15	19	(20%)	(17%)
Tygacil	50	60	(17%)	(14%)	4	6	(34%)	(30%)	46	54	(15%)	(12%)	7	15	(54%)	(52%)	1	1	—	—	38	38	—	2%
Pfizer CentreOne ^(a)	176	159	11%	12%	101	81	24%	24%	75	78	(3%)	(1%)	30	31	(2%)	(—)	5	5	7%	7%	40	42	(6%)	(2%)
All other Anti-infectives	335	300	12%	14%	95	70	35%	35%	240	230	5%	8%	69	65	5%	9%	26	28	(6%)	(6%)	146	137	6%	11%
All other Hospital ^(a)	656	669	(2%)	(1%)	386	399	(3%)	(2%)	270	270	—	3%	43	49	(11%)	(8%)	82	85	(3%)	(—)	144	136	5%	9%
Vaccines	1,808	1,845	(2%)	(1%)	1,078	1,149	(6%)	(5%)	730	695	5%	8%	234	229	2%	6%	93	103	(10%)	(9%)	403	363	11%	14%
Prevnar 13/Prevenar 13	1,603	1,660	(3%)	(3%)	1,008	1,089	(7%)	(6%)	595	571	4%	7%	132	136	(4%)	(—)	87	94	(8%)	(7%)	376	340	11%	13%
FSME/MMUN-TicoVac	64	57	13%	17%	—	—	—	—	64	57	13%	17%	55	52	6%	10%	—	—	—	—	9	5	82%	88%
Nimenrix	52	46	13%	18%	—	—	—	—	52	46	13%	18%	30	22	37%	43%	5	8	(34%)	(30%)	17	16	2%	7%
Trumenba	73	61	19%	19%	70	60	16%	16%	3	1	—	—	2	1	—	—	—	—	—	—	1	—	—	—
All other Vaccines	16	21	(23%)	(20%)	—	—	—	—	16	21	(23%)	(20%)	14	18	(20%)	(17%)	1	1	(39%)	(38%)	1	2	(49%)	(47%)
Inflammation & Immunology (I&I)^(a)	1,226	1,184	4%	6%	566	447	27%	(24%)	660	737	(11%)	(7%)	328	406	(19%)	(16%)	162	160	1%	1%	170	171	(1%)	8%
Xeljanz	599	432	38%	40%	444	332	34%	34%	154	100	54%	61%	62	30	—	—	55	41	33%	34%	38	29	30%	46%
Embrel (Outside the U.S. and Canada)	415	531	(22%)	(19%)	—	—	—	—	415	531	(22%)	(19%)	199	298	(33%)	(31%)	88	101	(13%)	(14%)	128	133	(4%)	4%
Inflectra/Remsima ^{(a),(b)}	155	166	(7%)	(5%)	77	71	8%	8%	78	95	(18%)	(15%)	65	79	(18%)	(15%)	9	6	37%	41%	5	10	(49%)	(49%)
Eucrisa	43	40	7%	7%	42	40	5%	5%	1	—	—	—	—	—	—	—	1	—	—	—	—	—	—	—
All other I&I	15	14	8%	6%	3	4	(13%)	(12%)	12	10	16%	14%	2	(1)	—	—	10	11	(11%)	(13%)	—	—	—	—
Rare Disease	601	531	13%	16%	222	157	42%	(38%)	379	374	1%	6%	186	201	(8%)	(4%)	103	90	14%	14%	91	83	9%	20%
BeneFIX	125	132	(5%)	(3%)	68	57	15%	15%	59	74	(20%)	(16%)	25	36	(32%)	(29%)	17	21	(16%)	(13%)	17	18	(3%)	6%
Genotropin	124	143	(13%)	(11%)	23	35	(34%)	(30%)	101	108	(7%)	(4%)	39	45	(14%)	(10%)	37	39	(4%)	(5%)	25	24	4%	11%
Refacto AF/Xyntha	104	117	(11%)	(7%)	22	27	(18%)	(13%)	82	90	(9%)	(7%)	48	57	(16%)	(13%)	9	10	(11%)	(6%)	25	23	8%	21%
Vyndagel	156	37	—	—	79	—	—	—	77	37	—	—	40	23	73%	80%	29	11	—	—	8	3	—	—
Sonavert	64	64	—	3%	24	23	4%	4%	40	41	(2%)	(2%)	31	33	(6%)	(1%)	5	5	7%	6%	4	3	15%	26%
All other Rare Disease	28	38	(26%)	(21%)	8	14	(43%)	(38%)	20	24	(16%)	(8%)	3	7	(60%)	(58%)	5	5	2%	6%	12	12	3%	16%
UPJOHN^{(a),(b)}	2,195	3,036	(28%)	(26%)	509	1,231	(59%)	(54%)	1,686	1,805	(7%)	(4%)	233</											

Pfizer Inc. Revenues
Second Quarter 2019 and 2018
Unaudited
(millions of dollars)
Quarter-to-Date

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL ^(a)				DEVELOPED EUROPE ^(a)				DEVELOPED REST OF WORLD ^(a)				EMERGING MARKETS ^(a)				
	2019		2018		2019		2018		2019		2018		2019		2018		2019		2018		2019		2018	
	Reported	% of Change	Operational	% of Change	Reported	% of Change	Reported	% of Change	Reported	% of Change	Operational	% of Change	Reported	% of Change	Operational	% of Change	Reported	% of Change	Operational	% of Change	Reported	% of Change	Operational	% of Change
TOTAL REVENUES	13,264	13,466	(2%)	2%	6,335	6,225	2%	6,335	6,225	2%	6,335	6,225	2%	6,335	6,225	2%	6,335	6,225	2%	6,335	6,225	2%	6,335	6,225
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)^(a)	9,595	9,434	2%	6%	4,743	4,509	5%	4,743	4,509	5%	4,743	4,509	5%	4,743	4,509	5%	4,743	4,509	5%	4,743	4,509	5%	4,743	4,509
Internal Medicine^(a)	2,330	2,276	2%	6%	1,262	1,161	9%	1,262	1,161	9%	1,262	1,161	9%	1,262	1,161	9%	1,262	1,161	9%	1,262	1,161	9%	1,262	1,161
Eliquis alliance revenues and direct sales	1,085	889	22%	26%	626	482	30%	626	482	30%	459	407	13%	21%	265	247	7%	16%	91	87	5%	10%	103	73
Chantix/Champix	276	277	—	1%	227	217	5%	227	217	5%	49	60	(19%)	(12%)	22	20	9%	17%	18	30	(39%)	(35%)	8	10
Piemarin family	193	210	(8%)	(8%)	162	197	(8%)	162	197	(8%)	11	13	(16%)	(11%)	—	1	(18%)	(13%)	5	5	(2%)	3%	5	7
BMP2	79	80	(2%)	(2%)	79	80	(2%)	79	80	(2%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Toviaz	65	70	(7%)	(2%)	19	21	(9%)	19	21	(9%)	46	49	(6%)	—	17	18	(7%)	—	26	28	(5%)	(2%)	3	3
All other Internal Medicine	631	750	(16%)	(10%)	128	164	(22%)	128	164	(22%)	503	586	(14%)	(7%)	114	158	(28%)	(21%)	185	197	(6%)	(3%)	205	231
Oncology^(a)	2,236	1,888	18%	23%	1,386	1,178	18%	1,386	1,178	18%	851	710	20%	31%	420	357	18%	27%	162	145	11%	16%	269	208
Ibrance	1,261	1,027	23%	27%	831	744	12%	831	744	12%	430	283	52%	67%	250	173	44%	56%	79	58	36%	42%	101	52
Sutent	248	275	(10%)	(4%)	82	94	(13%)	82	94	(13%)	166	181	(8%)	1%	74	81	(8%)	(1%)	25	32	(22%)	(18%)	67	69
Xtandi alliance revenues	201	171	18%	18%	201	171	18%	201	171	18%	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Xalkori	133	137	(3%)	2%	41	42	(3%)	41	42	(3%)	92	96	(4%)	4%	29	40	(28%)	(22%)	13	15	(17%)	(13%)	51	41
Bosulfif	97	77	25%	27%	64	52	21%	64	52	21%	33	25	32%	40%	16	13	27%	37%	12	11	13%	17%	5	2
Inlyta	104	81	28%	34%	60	33	82%	4%	44	48	(9%)	—	—	10	13	(17%)	(11%)	18	21	(16%)	(13%)	16	15	
Retacrit ^(a)	51	18	—	—	30	—	—	—	21	18	19%	29%	—	21	16	32%	43%	—	—	—	—	—	—	2
All other Oncology	140	100	41%	45%	76	41	85%	—	64	59	9%	16%	—	20	22	(10%)	(3%)	15	9	79%	86%	29	28	
Hospital^(a)	1,913	2,077	(8%)	(4%)	752	829	(9%)	752	829	(9%)	1,161	1,248	(7%)	(1%)	231	268	(14%)	(8%)	182	217	(16%)	(12%)	748	763
Sulperazon	165	150	10%	17%	—	—	—	—	165	150	10%	17%	—	—	—	—	—	—	2	3	(13%)	(10%)	163	148
Medrol ^(a)	120	123	(2%)	—	63	62	1%	—	57	61	(6%)	(1%)	—	17	19	(12%)	(5%)	12	6	81%	88%	28	35	
Vfend	94	110	(15%)	(8%)	3	2	66%	—	90	108	(16%)	(10%)	—	5	10	(48%)	(44%)	19	21	(10%)	(7%)	66	77	
Zithromax ^(a)	73	81	(10%)	(5%)	—	3	(87%)	—	73	79	(8%)	(2%)	—	12	12	(1%)	7%	9	10	(8%)	(5%)	52	57	
EpiPen	80	95	(16%)	(15%)	67	75	(11%)	—	13	20	(34%)	(31%)	—	—	—	—	—	13	20	(34%)	(31%)	—	—	
Zyvox	71	66	8%	13%	13	(3)	—	—	58	69	(16%)	(11%)	—	3	5	(31%)	(25%)	13	15	(13%)	(10%)	41	49	
Fragmin	63	74	(15%)	(9%)	2	4	(38%)	—	61	71	(14%)	(8%)	—	29	38	(23%)	(18%)	17	18	(10%)	(6%)	15	14	
Zosyn/Tazocin	53	58	(9%)	(6%)	35	39	(11%)	—	19	20	(5%)	3%	—	2	7	(76%)	(76%)	1	1	—	4%	17	16	
Pfizer CentreOne ^(a)	204	209	(2%)	—	98	120	(18%)	—	106	89	18%	25%	—	48	35	38%	44%	4	3	27%	27%	54	51	
All other Anti-infectives	367	362	1%	7%	84	71	19%	—	283	292	(3%)	4%	—	78	91	(14%)	(8%)	28	29	(4%)	—	177	172	
All other Hospital ^(a)	623	748	(17%)	(15%)	387	458	(16%)	—	236	290	(18%)	(13%)	—	38	56	(33%)	(27%)	64	89	(28%)	(24%)	135	145	
Vaccines	1,375	1,400	(2%)	2%	634	702	(10%)	634	702	(10%)	741	698	6%	13%	263	239	10%	19%	102	109	(6%)	(1%)	376	350
Prevnar 13/Prevenar 13	1,179	1,250	(6%)	(3%)	612	682	(10%)	—	567	568	—	6%	—	134	141	(5%)	2%	—	93	107	(13%)	(9%)	340	320
FSME/IMMUN-TicoVac	95	73	31%	41%	—	—	—	—	95	73	31%	41%	—	81	59	37%	47%	—	—	—	—	14	14	
Nimenrix	58	30	94%	—	—	—	—	—	58	30	94%	—	—	31	19	62%	75%	8	1	—	—	19	10	
All other Vaccines	43	47	(9%)	(6%)	22	21	6%	—	21	27	(20%)	(14%)	—	17	20	(12%)	(5%)	2	1	—	—	2	6	
Inflammation & Immunology (I&I)^(a)	1,219	1,222	—	5%	560	485	15%	560	485	15%	659	737	(11%)	(2%)	341	394	(13%)	(6%)	151	141	6%	11%	167	202
Xeljanz	613	463	32%	36%	458	379	21%	—	155	84	85%	—	—	64	26	—	—	50	31	60%	68%	41	26	
Enbrel (Outside the U.S. and Canada)	420	551	(24%)	(16%)	—	—	—	—	420	551	(24%)	(16%)	—	217	293	(26%)	(20%)	82	92	(11%)	(7%)	121	166	
Inflectra/Remsima ^{(a),(b)}	153	158	(4%)	—	74	63	17%	—	78	95	(17%)	(11%)	—	66	80	(17%)	(11%)	7	6	29%	36%	5	9	
Eucrisa	27	39	(30%)	(30%)	26	39	(33%)	—	1	—	—	—	—	1	—	—	—	1	—	—	—	—	—	
All other I&I	6	11	(44%)	(44%)	1	3	(67%)	—	5	7	(33%)	(34%)	—	(6)	(5)	(9%)	(17%)	11	13	(16%)	(13%)	—	—	
Rare Disease	521	571	(9%)	(2%)	149	154	(3%)	149	154	(3%)	372	418	(11%)	(2%)	185	219	(16%)	(9%)	93	100	(7%)	(2%)	94	98
BeneFIX	121	141	(14%)	(10%)	59	58	2%	—	62	83	(25%)	(18%)	—	25	43	(41%)	(36%)	18	22	(17%)	(12%)	18	18	
Genotropin	125	140	(11%)	(4%)	21	29	(27%)	—	104	111	(6%)	2%	—	41	45	(8%)	(1%)	39	43	(9%)	(5%)	24	23	
Refacto AF/Xyntha	108	141	(23%)	(16%)	22	24	(9%)	—	87	117	(26%)	(18%)	—	50	66	(25%)	(19%)	10	13	(26%)	(20%)	27	37	
Somavert	68	68	1%	6%	29	27	7%	—	40	41	(3%)	5%	—	32	33	(3%)	5%	5	5	(5%)	(1%)	3	3	
Vyndaqel	63	38	63%	73%	8	—	—	—	55	38	42%	53%	—	34	24	43%	55%	17	12	38%	42%	4	3	
All other Rare Disease	35	43	(18%)	(8%)	11	16	(33%)	—	25	27	(9%)	6%	—	4	8	(57%)	(55%)	5	5	1%	7%	16	14	
UPJOHN^{(a),(b)}	2,807	3,147	(11%)	(7%)	1,169	1,282	(9%)	1,169	1,282	(9%)	1,638	1,865	(12%)	(7%)	243	280	(13%)	(7%)	544	557	(2%)	2%	851	1,028
Lyricea	1,175	1,223	(4%)	(3%)	835	861	(3%)	—	340	362	(6%)	(1%)	—	53	65	(19%)	(12%)	213	222	(4%)	—	75	75	
Lipitor	407	521	(22%)	(17%)	30	32	(8%)	—	377	489	(23%)	(17%)	—	42	46	(9%)	(2%)							

Pfizer Inc. Revenues
First Quarter 2019 and 2018
Unaudited
(millions of dollars)
Quarter-to-Date

	WORLDWIDE				UNITED STATES			TOTAL INTERNATIONAL ^(a)				DEVELOPED EUROPE ^(a)				DEVELOPED REST OF WORLD ^(a)				EMERGING MARKETS ^(a)			
			% of Change				% of Change			% of Change				% of Change				% of Change					
	2019	2018	Reported	Operational	2019	2018	Reported	2019	2018	Reported	Operational	2019	2018	Reported	Operational	2019	2018	Reported	Operational	2019	2018	Reported	Operational
TOTAL REVENUES	13,118	12,906	2%	5%	6,175	6,275	(2%)	6,943	6,631	5%	12%	2,086	2,092	—	6%	1,535	1,461	5%	7%	3,322	3,078	8%	17%
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)^(b)	9,185	8,881	3%	7%	4,521	4,388	3%	4,664	4,493	4%	11%	1,762	1,721	2%	9%	958	911	5%	8%	1,944	1,861	4%	15%
Internal Medicine^(c)	2,217	2,071	7%	10%	1,181	1,087	9%	1,036	984	5%	12%	428	377	13%	21%	292	292	—	2%	316	315	1%	12%
Eliquis alliance revenues and direct sales	1,011	765	32%	36%	601	435	38%	410	330	24%	33%	239	191	25%	34%	79	68	17%	19%	92	71	29%	44%
Chantix/Champix	273	251	8%	10%	212	188	13%	61	64	(4%)	1%	20	21	(6%)	—	17	28	(38%)	(35%)	24	14	64%	72%
Premarin family	168	191	(12%)	(12%)	158	180	(12%)	10	11	(6%)	1%	—	—	—	—	5	6	(20%)	(16%)	5	5	10%	20%
BMP2	67	73	(8%)	(8%)	67	73	(8%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Toviaz	60	60	(1%)	2%	17	18	(10%)	43	42	3%	7%	17	17	(3%)	3%	24	22	9%	10%	3	3	(8%)	15%
All other Internal Medicine	639	730	(13%)	(8%)	127	192	(34%)	512	538	(5%)	1%	152	148	3%	9%	167	169	(1%)	—	193	221	(13%)	(2%)
Oncology^(d)	1,961	1,760	11%	15%	1,179	1,135	4%	782	625	25%	36%	393	300	31%	40%	153	113	35%	37%	236	212	11%	29%
Ibrance	1,133	933	21%	25%	741	726	2%	392	207	90%	*	228	116	97%	*	74	41	80%	82%	90	49	82%	*
Sutent	232	262	(12%)	(6%)	71	88	(19%)	161	174	(8%)	1%	76	80	(5%)	1%	26	27	(6%)	(3%)	59	67	(12%)	2%
Xtandi alliance revenues	168	159	6%	6%	168	159	6%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Xalkori	123	153	(20%)	(16%)	34	42	(19%)	88	110	(20%)	(14%)	29	46	(36%)	(32%)	13	15	(12%)	(9%)	46	50	(8%)	—
Bosulif	80	60	33%	35%	54	41	31%	27	20	36%	42%	15	10	44%	53%	10	8	31%	31%	2	2	15%	26%
Inlyta	73	74	(1%)	4%	33	28	17%	40	46	(12%)	(4%)	9	13	(32%)	(28%)	17	17	(4%)	(4%)	15	15	(4%)	15%
All other Oncology	153	119	28%	31%	79	51	54%	74	68	9%	15%	36	34	6%	12%	13	5	*	*	24	28	(15%)	(9%)
Hospital^(e)	1,887	2,026	(7%)	(3%)	752	820	(6%)	1,135	1,206	(6%)	—	219	259	(15%)	(10%)	184	179	3%	7%	732	768	(5%)	2%
Sulperazon	177	168	5%	11%	—	—	—	177	168	5%	11%	—	—	—	—	2	2	(13%)	(14%)	175	166	5%	11%
Medrol ^(f)	120	136	(12%)	(10%)	70	83	(16%)	50	52	(5%)	—	17	18	(9%)	(3%)	8	5	42%	47%	25	28	(11%)	(6%)
Zithromax ^(g)	104	101	4%	9%	(3)	2	*	107	99	8%	13%	15	17	(12%)	(6%)	10	11	(2%)	(1%)	82	71	15%	20%
Vtend ^(h)	85	98	(13%)	(8%)	4	2	*	81	96	(16%)	(10%)	6	10	(45%)	(41%)	18	20	(11%)	(10%)	57	66	(13%)	(5%)
EpiPen	66	52	26%	27%	56	45	26%	10	8	28%	35%	—	—	—	—	10	8	28%	35%	—	—	—	—
Zyvox ⁽ⁱ⁾	64	68	(7%)	(3%)	5	6	(9%)	58	63	(7%)	(3%)	3	6	(44%)	(40%)	13	12	16%	16%	42	45	(8%)	(3%)
Fragmin	60	70	(15%)	(9%)	2	4	(52%)	58	66	(13%)	(7%)	29	37	(21%)	(18%)	14	18	(23%)	(18%)	15	11	30%	40%
Zosyn/Tazocin	51	61	(17%)	(15%)	35	43	(18%)	16	19	(14%)	(6%)	—	1	(76%)	(75%)	1	2	(49%)	(47%)	15	16	(5%)	4%
Pfizer CentreOne ^(j)	176	171	3%	4%	97	96	1%	79	75	4%	8%	37	24	57%	62%	3	2	13%	13%	39	49	(21%)	(18%)
All other Anti-infectives	354	392	(10%)	(5%)	93	107	(13%)	261	285	(9%)	(2%)	70	85	(18%)	(12%)	26	25	4%	6%	165	175	(6%)	2%
All other Hospital ^(k)	631	708	(11%)	(9%)	391	432	(9%)	240	275	(13%)	(8%)	42	61	(31%)	(27%)	80	75	7%	13%	118	140	(16%)	(11%)
Vaccines	1,612	1,463	10%	13%	894	837	7%	718	626	15%	22%	226	198	14%	22%	92	106	(13%)	(11%)	400	322	24%	33%
Pvencar 13/Prevenar 13	1,486	1,380	8%	10%	878	826	6%	608	555	10%	16%	143	141	1%	8%	86	103	(17%)	(14%)	379	310	22%	31%
All other Vaccines	126	83	53%	63%	17	11	44%	110	71	54%	66%	83	57	47%	57%	6	3	*	*	21	12	76%	95%
Inflammation & Immunology (I&I)^(l)	1,037	1,013	2%	8%	378	338	12%	659	675	(2%)	6%	325	380	(14%)	(9%)	151	133	13%	16%	182	162	13%	34%
Enbrel (Outside the U.S. and Canada)	451	506	(11%)	(3%)	—	—	—	451	506	(11%)	(3%)	217	290	(25%)	(21%)	93	89	4%	5%	141	126	12%	32%
Xeljanz	423	326	30%	34%	298	253	18%	125	72	72%	89%	45	19	*	*	43	29	49%	54%	36	24	49%	82%
Infectra/Remsimba	138	145	(4%)	—	57	55	5%	81	90	(10%)	(4%)	71	75	(6%)	—	5	4	40%	50%	5	11	(54%)	(50%)
Eucrisa	22	26	(12%)	(12%)	22	26	(14%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
All other I&I	3	11	(74%)	(79%)	—	4	(94%)	3	6	(61%)	(69%)	(7)	(5)	(52%)	(62%)	10	11	(13%)	(13%)	—	—	—	—
Rare Disease	470	549	(14%)	(9%)	137	172	(20%)	333	377	(12%)	(4%)	170	207	(18%)	(13%)	86	87	(1%)	1%	78	83	(7%)	11%
BeneFIX	125	147	(15%)	(11%)	65	68	(4%)	60	79	(24%)	(18%)	26	40	(36%)	(32%)	19	21	(11%)	(8%)	15	17	(12%)	2%
Genotropin	107	132	(19%)	(14%)	13	31	(60%)	95	101	(6%)	—	38	44	(13%)	(7%)	36	35	2%	3%	21	22	(7%)	9%
Refacto AF/Xyntha	106	130	(19%)	(13%)	27	30	(10%)	79	100	(21%)	(13%)	46	64	(28%)	(24%)	11	14	(21%)	(15%)	22	23	(2%)	17%
Somavert	59	63	(5%)	(1%)	22	24	(10%)	38	39	(2%)	5%	31	31	(1%)	6%	4	4	(11%)	(8%)	3	3	(3%)	19%
All other Rare Disease	72	76	(6%)	2%	10	18	(43%)	62	58	6%	16%	29	28	4%	11%	16	12	30%	32%	16	18	(8%)	14%
UPJOHN^(m)	3,075	3,120	(1%)	1%	1,213	1,408	(14%)	1,861	1,712	9%	14%	217	266	(19%)	(13%)	492	465	6%	7%	1,152	981	17%	25%
Lyrica	1,186	1,213	(2%)	(1%)	889	907	(2%)	298	307	(3%)	—	45	63	(29%)	(24%)	189	169	12%	12%	63	74	(14%)	(8%)
Lipitor	622	511	22%	28%	21	29	(26%)	601	483	25%	31%	38	44	(14%)	(8%)	50	46	9%	12%	513	393	31%	38%
Novvasc	300	256	17%	24%	10	9	10%	289	246	17%	24%	15	17	(14%)	(8%)	41	45	(9%)	(7%)	234	184	27%	35%
Celebrex	174	145	20%	23%	15	16	(6%)	159	129	23%	27%	6	6	(9%)	(3%)	71	60	18%	18%	82	63	31%	38%
Viagra	145	187	(22%)	(19%)	40	88	(55%)	105	99	7%	14%	8	9	(13%)	(7%)	15	16	(4%)	—	82	73	11%	19%
Efexor	77	71	8%	13%	17	18	(5%)	60	53	13%	19%	12	14	(17%)	(12%)	27	20	37%	39%	22	19	11%	21%
Zolof	69	74	(7%)	—	11	16	(27%)	58	59	(1%)	7%	7	10	(23%)	(19%)	12	14	(12%)	(11%)	38	35	9%	21%
Xalatan/Xalacom	62	72	(14%)	(10%)	5	5	15%	56	67	(16%)	(12%)	14	15	(8%)	(2%)	25	29	(14%)	(13%)	18	23		

Pfizer Inc. Revenues -- Recast to Reflect 2019 Commercial Operating Structure**
Full Year 2018 and 2017
Unaudited
(millions of dollars)
Year-To-Date

	WORLDWIDE				UNITED STATES				TOTAL INTERNATIONAL ^(a)				DEVELOPED EUROPE ^(m)				DEVELOPED REST OF WORLD ⁽ⁿ⁾				EMERGING MARKETS ^(o)			
			% of Change				% of Change				% of Change				% of Change				% of Change					
	2018	2017	Reported	Operational	2018	2017	Reported	Operational	2018	2017	Reported	Operational	2018	2017	Reported	Operational	2018	2017	Reported	Operational	2018	2017	Reported	Operational
TOTAL REVENUES	\$ 53,647	\$ 52,546	2%	2%	\$ 25,329	\$ 26,026	(3%)		\$ 28,318	\$ 26,519	7%	6%	\$ 9,116	\$ 8,508	7%	2%	\$ 6,551	\$ 6,612	(1%)	(2%)	\$ 12,651	\$ 11,399	11%	13%
PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)^(b)	\$ 37,558	\$ 35,530	6%	5%	\$ 18,243	\$ 17,961	2%		\$ 19,315	\$ 17,569	10%	9%	\$ 7,540	\$ 6,747	12%	6%	\$ 4,080	\$ 4,005	2%	1%	\$ 7,695	\$ 6,817	13%	16%
Internal Medicine^(c)	\$ 8,869	\$ 8,229	8%	7%	\$ 4,542	\$ 4,321	5%		\$ 4,327	\$ 3,908	11%	10%	\$ 1,707	\$ 1,391	23%	17%	\$ 1,312	\$ 1,333	(2%)	(3%)	\$ 1,308	\$ 1,184	11%	16%
Eliquis alliance revenues and direct sales	3,434	2,523	36%	35%	1,849	1,418	30%		1,585	1,105	43%	40%	947	630	50%	44%	333	275	21%	20%	304	200	52%	56%
Chantix/Champix	1,085	997	9%	8%	838	742	13%		247	255	(3%)	(5%)	83	78	7%	2%	111	134	(17%)	(18%)	52	43	22%	26%
Premarin family	832	977	(15%)	(15%)	783	921	(15%)		49	56	(12%)	(12%)	2	2	(20%)	(23%)	23	27	(12%)	(12%)	24	27	(12%)	(11%)
BMP2	279	261	7%	7%	278	261	6%		1	—	*	*	—	—	—	—	—	—	—	—	1	—	*	*
Toviaz	271	257	5%	4%	87	85	3%		183	173	6%	4%	71	67	6%	1%	101	95	6%	5%	11	11	4%	14%
Pristiq	206	303	(32%)	(32%)	71	133	(47%)		135	170	(20%)	(20%)	32	28	15%	9%	44	69	(37%)	(37%)	59	73	(18%)	(15%)
All other Internal Medicine	2,763	2,910	(5%)	(5%)	636	761	(16%)		2,127	2,149	(1%)	(1%)	571	585	(2%)	(7%)	700	733	(5%)	(6%)	857	831	3%	9%
Vaccines	\$ 6,332	\$ 6,001	6%	5%	\$ 3,469	\$ 3,422	1%		\$ 2,863	\$ 2,580	11%	11%	\$ 974	\$ 893	9%	4%	\$ 420	\$ 445	(5%)	(7%)	\$ 1,469	\$ 1,242	18%	22%
Prevnar 13/Prevenar 13	5,802	5,601	4%	4%	3,360	3,334	1%		2,443	2,268	8%	8%	655	643	2%	(2%)	402	432	(7%)	(8%)	1,386	1,193	16%	20%
FSME/MMUN-TicoVac	184	134	37%	28%	—	—	—		184	134	37%	28%	158	116	37%	29%	—	—	—	—	25	18	37%	24%
Trumenba	116	88	31%	31%	109	88	24%		7	—	*	*	6	—	—	—	—	—	—	1	—	*	*	
All other Vaccines	230	177	29%	29%	—	—	—		230	177	29%	29%	155	134	15%	10%	18	13	40%	44%	57	30	88%	*
Oncology^(d)	\$ 7,471	\$ 6,304	19%	18%	\$ 4,657	\$ 4,392	6%		\$ 2,814	\$ 1,912	47%	46%	\$ 1,436	\$ 848	69%	61%	\$ 573	\$ 355	61%	59%	\$ 806	\$ 708	14%	21%
Ibrance	4,118	3,126	32%	32%	2,922	2,825	3%		1,196	300	*	*	725	124	*	*	245	34	*	*	226	143	58%	84%
Sutent	1,049	1,081	(3%)	(4%)	357	374	(4%)		692	707	(2%)	(3%)	323	323	—	(5%)	119	121	(2%)	(4%)	250	262	(5%)	(1%)
Xtandi alliance revenues	699	590	18%	18%	—	—	—		—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Xalkori	524	594	(12%)	(14%)	158	223	(29%)		366	371	(1%)	(4%)	154	175	(12%)	(18%)	58	56	4%	1%	154	139	11%	11%
Inlyta	298	339	(12%)	(12%)	119	126	(5%)		178	213	(16%)	(16%)	48	70	(31%)	(35%)	77	86	(10%)	(12%)	53	57	(8%)	(1%)
Bosulif	296	233	27%	26%	196	156	26%		99	77	28%	25%	52	40	29%	23%	39	32	24%	22%	8	5	56%	55%
All other Oncology	488	340	43%	41%	205	98	*		283	243	17%	13%	134	116	16%	9%	34	26	31%	30%	115	101	14%	13%
Inflammation & Immunology (I&I)^(e)	\$ 4,720	\$ 4,386	8%	7%	\$ 1,816	\$ 1,384	31%		\$ 2,904	\$ 3,002	(3%)	(4%)	\$ 1,574	\$ 1,692	(7%)	(12%)	\$ 577	\$ 559	3%	2%	\$ 753	\$ 750	—	9%
Enbrel (Outside the U.S. and Canada)	2,112	2,452	(14%)	(14%)	—	—	—		2,112	2,452	(14%)	(14%)	1,152	1,410	(18%)	(23%)	358	395	(10%)	(10%)	603	647	(7%)	1%
Xeljanz	1,774	1,345	32%	33%	1,394	1,133	23%		380	212	79%	84%	121	39	*	*	148	97	52%	52%	110	76	45%	64%
Infectra/Remsimia	642	419	53%	50%	259	118	*		383	401	27%	23%	319	261	22%	16%	24	13	91%	92%	40	27	49%	50%
Eucrisa	147	67	*	*	147	67	*		—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
All other I&I	45	103	(57%)	(57%)	16	66	(75%)		28	37	(23%)	(24%)	(18)	(18)	(1%)	3%	46	54	(15%)	(16%)	—	—	—	—
Rare Disease	\$ 2,211	\$ 2,240	(1%)	(2%)	\$ 652	\$ 632	3%		\$ 1,560	\$ 1,608	(3%)	(5%)	\$ 835	\$ 892	(6%)	(11%)	\$ 368	\$ 388	(5%)	(6%)	\$ 357	\$ 328	9%	16%
Genotropin	558	532	5%	4%	130	98	33%		428	434	(1%)	(3%)	179	177	2%	(3%)	156	160	(2%)	(4%)	92	97	(5%)	1%
BeneFIX	554	604	(8%)	(9%)	245	253	(3%)		309	351	(12%)	(13%)	153	192	(20%)	(25%)	82	99	(17%)	(19%)	74	60	24%	32%
Refacto AF/Xyntha	514	551	(7%)	(8%)	109	114	(4%)		404	438	(8%)	(9%)	245	291	(16%)	(20%)	48	53	(8%)	(9%)	111	94	18%	24%
Somavert	267	254	5%	3%	103	95	8%		164	158	4%	—	130	125	4%	(1%)	20	18	8%	7%	14	15	(7%)	1%
All other Rare Disease	318	300	6%	6%	64	72	(10%)		254	228	11%	11%	127	108	17%	11%	62	57	8%	6%	66	63	5%	15%
Hospital^(f)	\$ 7,955	\$ 8,369	(5%)	(6%)	\$ 3,107	\$ 3,810	(18%)		\$ 4,848	\$ 4,559	6%	5%	\$ 1,015	\$ 1,031	(1%)	(6%)	\$ 830	\$ 925	(10%)	(11%)	\$ 3,002	\$ 2,604	15%	15%
Sulperazon	613	471	30%	27%	—	—	—		613	471	30%	27%	—	—	—	—	10	12	(18%)	(20%)	603	460	31%	28%
Medrol ^(g)	493	540	(9%)	(10%)	266	318	(17%)		227	221	3%	1%	74	73	2%	(4%)	26	26	—	—	127	123	4%	3%
Vlend ^(h)	392	421	(7%)	(7%)	10	13	(24%)		382	407	(6%)	(6%)	36	57	(37%)	(41%)	80	104	(23%)	(25%)	267	246	8%	9%
EpiPen	303	290	4%	4%	242	221	9%		62	70	(11%)	(12%)	—	—	—	—	62	70	(11%)	(12%)	—	—	—	—
Fragmin	293	306	(4%)	(7%)	14	20	(31%)		279	286	(2%)	(5%)	143	148	(4%)	(8%)	75	79	(5%)	(6%)	61	59	4%	2%
Zithromax ⁽ⁱ⁾	326	299	9%	6%	7	4	81%		319	295	8%	5%	52	49	7%	0%	41	50	(18%)	(20%)	226	197	15%	13%
Tygacil	249	260	(5%)	(6%)	25	45	(44%)		223	215	4%	2%	66	78	(15%)	(21%)	6	6	(10%)	(13%)	151	131	16%	16%
Zyvox ^(j)	236	281	(16%)	(18%)	(3)	15	(122%)		239	266	(10%)	(12%)	15	28	(47%)	(51%)	55	65	(15%)	(17%)	169	172	(2%)	(4%)
Zosyn/Tazocin	230	195	18%	19%	151	160	(6%)		79	35	*	*	5	2	*	*	5	2	*	*	70	31	*	*
Precedex	213	243	(12%)	(12%)	97	140	(31%)		116	104	12%	12%	—	—	—	—	68	57	20%	19%	48	47	3%	4%
Pfizer CentreOne ^(k)	755	706	7%	6%	409	537	(24%)		345	169	*	*	138	109	26%	26%	15	18	(14%)	(14%)	192	43	*	*
All other Anti-infectives	1,230	1,417	(13%)	(14%)	299	512	(42%)		931	905	3%	2%	274	239	15%	8%	106	112	(5%)	(6%)	551	554	(1%)	2%
All other Hospital ^(l)	2,623	2,939	(11%)	(11%)	1,591	1,824	(13%)		1,032	1,115	(7%)	(9%)	213	248	(14%)	(19%)	282	325	(13%)	(13%)	536	542	(1%)	(2%)
UPJOHN^(m)	\$ 12,484	\$ 13,447	(7%)	(8%)	\$ 5,209	\$ 6,150	(15%)		\$ 7,275	\$ 7,297	—	(2%)	\$ 1,102	\$ 1,330	(17%)	(21%)	\$ 2,140	\$ 2,286	(6%)	(8%)	\$ 4,033	\$ 3,681	10%	9%
Lyrica	4,970	5,065	(2%)	(2%)	3,594	3,463	4%		1,375	1,601	(14%)	(15%)	257	438	(41%)	(44%)	817	832	(2%)	(3%)	301	331	(9%)	(7%)
Lipitor	2,062	1,915	8%	5%	110	161	(31%)		1,952	1,754	11%	9%	183	183	—	(6%)	213	285	(25%)	(28%)	1,557	1,285	21%	19%
Norvasc	1,029	932	10%	9%	36	38	(5%)		992	894	11%	9%	67	65	2%	(3%)	185	213	(13%)	(15%)	741	616	20%	19%

PFIZER INC.
Notes to Revenue Table Information

-
- (a) Total International represents Developed Europe region + Developed Rest of World region + Emerging Markets region. Details for these regions are described in footnotes (h) to (j) below, respectively.
-
- (b) Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan N.V. for generic drugs in Japan (Mylan-Japan). As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation.
-
- (c) Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Retacrit and Ruxience.
-
- (d) Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne^(e). All other Hospital primarily includes revenues from legacy Sterile Injectable Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in "All other Anti-infectives".
-
- (e) Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements.
-
- (f) On July 31, 2019, Pfizer's Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK's consumer healthcare business to form a new consumer healthcare joint venture, of which we own 32%. Upon the closing of the transaction, we deconsolidated our Consumer Healthcare business. Our financial results, and our Consumer Healthcare segment's operating results, for the third quarter of 2019 reflect one month of Consumer Healthcare segment's domestic operations and two months of Consumer Healthcare segment international operations. Likewise, our financial results, and our Consumer Healthcare segment's operating results, for the first nine months of 2019 reflect seven months of Consumer Healthcare segment domestic operations and eight months of Consumer Healthcare segment international operations. Our financial results for the third quarter and first nine months of 2020 do not reflect any contribution from the Consumer Healthcare business.
-
- (g) Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.
-
- (h) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.
-
- (i) Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.
-
- (j) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.
-